記述言語：英語   掲載種別：研究論文（学術雑誌）  

INTRODUCTION: Atopic dermatitis (AD) is a chronic relapsing condition with high disease burden and impact on health-related quality of life (HRQoL). Correlations between clinician- and patient-reported outcomes tend to be poor, and limited data in Asian patients are available. METHODS: ADDRESS-J was a prospective, non-interventional, longitudinal study that evaluated the real-world effectiveness and safety of AD treatment in Japanese adults (aged 20-59 years) with moderate-to-severe AD. Three clinician-reported AD severity outcomes (Investigator's Global Assessment, Eczema Area and Severity Index, and body surface area affected), three dermatological patient-reported outcomes (Patient-Oriented Eczema Measure, Dermatology Life Quality Index, and Worst Itch Numerical Rating Scale), and two general HRQoL patient-reported outcomes (5-dimension EuroQoL questionnaire and EuroQol Visual Analog Scale) were collected at baseline and every 3 months throughout the 24-month observation period. Four biomarkers were also analyzed when available (thymus and activation-regulated chemokine [TARC], lactate dehydrogenase [LDH], total immunoglobulin E [IgE], and peripheral blood eosinophil counts [PB EOS]). Spearman's correlation coefficients were calculated using all available pooled data from baseline through 24 months. RESULTS: Correlations between the three clinician-reported outcomes were high/very high (Spearman's correlation coefficients 0.76-0.92); those between the three dermatological patient-reported outcomes were moderate (0.53-0.64), and those between the clinician-reported and dermatological patient-reported outcomes were low/moderate (0.37-0.51). Correlations between the general HRQoL patient-reported outcomes and the clinician-reported and dermatological patient-reported outcomes were negligible-moderate (0.26-0.60). Biomarker correlations with the clinician-reported and dermatological patient-reported outcomes were low/moderate for TARC and LDH (0.44-0.63), but negligible/low for PB EOS and total IgE (0.01-0.41). CONCLUSIONS: These results show that clinician- and patient-reported outcomes do not necessarily correlate well in Japanese adults with AD. This highlights the importance of including patient-reported outcomes when assessing disease severity/impact, planning treatment, and assessing response to treatment. TRIAL REGISTRATION: UMIN Clinical Trials Registry (UMIN-CTR) Identifier UMIN000022623.

DOI： 10.1007/s13555-023-01094-9

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Senile lentigo (SL) is a pigmentary disorder associated with disrupted epidermal turnover. Trace minerals in the skin are known to regulate keratinocyte proliferation and differentiation. To clarify the role of iron in SL, we compared the expression of molecules related to iron metabolism between SL lesion (lesion) and the surrounding normal skin (nonlesion). Our results revealed that proteins involved in iron uptake and utilization such as transferrin receptor 1, iron regulatory protein 1, mitoferrin 1, and divalent metal transporter 1 were expressed in the lower epidermis in the nonlesion, while expression of them was also observed in the upper epidermis in the lesion. Ferroportin (FPN), involved in iron export, was expressed in the upper epidermis in the nonlesion, but was only scarcely expressed in the upper epidermis in the lesion. Hepcidin, which promotes FPN degradation, was expressed in the lower epidermis in the nonlesion; however, its expression was also observed in the upper epidermis in the lesion. These changes in the expression of molecules involved in iron uptake/export/utilization might reflect the altered iron utilization state in SL, resulting in disruption of keratinocyte differentiation and disturbing epidermal turnover. Our results suggest that the metabolism of iron in keratinocytes in SL differs from that in the normal epidermis, and these changes could be associated with the abnormal epidermal turnover and decreased melanin excretion in SL.

DOI： 10.1111/1346-8138.17034

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: Upadacitinib is an oral Janus kinase (JAK) 1 inhibitor approved in Japan for moderate-to-severe atopic dermatitis (AD), and it provides a high therapeutic efficacy. OBJECTIVES: We compared the therapeutic effects of upadacitinib on skin rashes of individual anatomical sites, head and neck, upper limbs, lower limbs, and trunk in patients with AD. METHODS: From August 2021 to December 2022, 65 Japanese patients with moderate-to-severe AD (aged ≥ 12 years) were treated with oral once daily upadacitinib 15 mg plus twice daily topical corticosteroids of moderate-to-strongest classes. RESULTS: The eczema area and severity indexes (EASIs) of individual sites decreased significantly at weeks 4, 12, and 24 compared to those at week 0 in parallel to total (whole body) EASI. The achievement rates of EASI 75 at week 24 and of EASI 90 at week 12 of lower limbs were significantly higher than those of trunk. The percent reductions of EASI of lower limbs at weeks 12 and 24 were significantly higher than those of head and neck and of trunk. CONCLUSIONS: Among the four anatomical sites, the treatment responsiveness to upadacitinib in lower limbs appeared the highest, while those in trunk and in head and neck appeared relatively lower.

DOI： 10.1080/09546634.2023.2212095

PubMed

researchmap

記述言語：英語  

DOI： 10.1016/j.alit.2023.12.001

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: Atopic dermatitis (AD) is a chronic eczematous disease with severe pruritus. Janus kinase (JAK) inhibitors, upadacitinib, baricitinib, and abrocitinib, are systemic treatments for AD. The outcomes of switching from one JAK inhibitor to another have not been examined. OBJECTIVES: We assessed the outcomes of switching from baricitinib 4 mg to upadacitinib 30 mg in Japanese patients with moderate-to-severe AD. METHODS: Twenty patients treated with baricitinib 4 mg, showing insufficient response or adverse events, were switched to treatment with upadacitinib 30 mg. We evaluated total eczema area and severity index (EASI), EASI at head and neck, trunk, upper, or lower limbs, EASI of erythema, edema/papulation, excoriation, or lichenification, and peak pruritus numerical-rating scale (PP-NRS) at baseline (start of baricitinib), weeks 0 (time of switching), and 4 and 12 after switching. RESULTS: Total EASI, EASI at each anatomical site, EASI of each clinical sign, and PP-NRS were markedly reduced at weeks 4 or 12 compared to week 0. Achievement rates of more than 75% or 90% reduction of EASI from baseline significantly improved after switching. CONCLUSIONS: Switching from baricitinib 4 mg to upadacitinib 30 mg effectively improved rash and pruritus.

DOI： 10.1080/09546634.2023.2276043

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Psoriasis is a chronic skin disease with interleukin (IL)-17-dominated inflammation and hyperproliferation of epidermis. Dietary fiber is fermented by the gut microbiome into short-chain fatty acids (SCFAs) that manifest anti-inflammatory effects. We examined if feeding with an inulin-enriched high-fiber diet (HFD) might improve topical imiquimod-induced psoriasis-like dermatitis in mice. HFD reduced thickening and total severity scores of imiquimod-induced dermatitis and reduced epidermal thickness, inflammatory infiltrates, including Ly6G+ neutrophils, and epidermal Ki67+ proliferating cells. HFD reduced mRNA levels of IL-17A, IL-17F, IL-22, IL-1β, tumor necrosis factor (TNF)-α, CXCL1, CXCL2, and keratin 16 and increased those of transforming growth factor (TGF)-β1 and cyclin-dependent kinase inhibitor 1A in imiquimod-induced dermatitis. In 16S rRNA sequencing of the gut microbiome, imiquimod increased relative abundance of phylum Firmicutes, while HFD increased that of phylum Bacteroidota and genus Bacteroides. HFD increased serum and fecal concentrations of SCFA propionate. Oral propionate reduced inflammatory infiltrates and epidermal Ki67+ cells and reduced mRNA levels of IL-17A, IL-17F, IL-17C, IL-22, IL-1β, IL-6, TNF-α, CXCL1, CCL20 and increased those of TGF-β1and IL-10 in imiquimod-indued dermatitis. Dietary inulin supplementation improves imiquimod-induced psoriasis-like dermatitis partially via propionate, and may be a promising adjunctive therapy for psoriasis.

DOI： 10.3390/ijms241814197

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Atopic dermatitis (AD) is a chronic eczematous disease with various types of rash, erythema, edema/papulation, excoriation, or lichenification. Janus kinase 1 inhibitor upadacitinib is effective for moderate-to-severe AD. We aimed to investigate the therapeutic effects of upadacitinib on each rash type in AD patients in real-world clinical practice. Seventy-two Japanese patients with moderate-to-severe AD were treated with oral upadacitinib 15 mg/day plus topical corticosteroids. The Eczema Area and Severity Index (EASI) scores for erythema, edema/papulation, excoriation, or lichenification on the whole body or on head and neck, upper limbs, lower limbs, or trunk were assessed at weeks 0, 4, and 12 of treatment. The proportions of patients who achieved resolution or at least 75% reduction of EASI from baseline (EASI 75) for individual rash types were calculated at weeks 4 and 12 on the whole body or each anatomical site. The resolution rates for excoriation, erythema, edema/papulation, or lichenification on the whole body were 38.3%, 23.7%, 21.7%, and 8.3% at week 4 and 18.3%, 18.6%, 11.6%, and 13.3% at week 12, respectively. The EASI scores for all rash types significantly decreased at weeks 4 and 12 compared to week 0. The achievement rates of EASI 75 for excoriation, erythema, edema/papulation, or lichenification on the whole body were 67.2%, 66.7%, 49.2%, and 37.7% at week 4 and 57.3%, 65%, 41%, and 41% at week 12, respectively. The achievement rate of EASI 75 for erythema on head and neck at week 4 (45.3%) was lower than that on upper limbs (71%) and on lower limbs (70.8%), and that on head and neck at week 12 (42.2%) was lower than that on lower limbs (69.2%). These results indicate that upadacitinib is effective for all AD rash types, especially for excoriation and erythema, while head-and-neck erythema might be less responsive to upadacitinib.

DOI： 10.1111/1346-8138.16950

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease. Dietary habits may modulate the pathogenesis of BP. OBJECTIVES: We evaluated dietary habits in Japanese patients with BP and compared their results to those of age- and sex-matched healthy controls. We also examined the relationship between dietary habits versus IgG anti-BP180NC16A antibody or parameters of BP disease area index (BPDAI); cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. MATERIALS & METHODS: Dietary habits were assessed by the validated, Brief-type self-administered Diet History Questionnaire. Severity of disease was assessed with BPDAI. RESULTS: Patients with BP showed a lower intake of retinol (vitamin A1) and beverages, and a higher intake of seasoning/spices, compared to controls. The bivariate and multivariable logistic regression analysis showed that BP was associated with a low intake of retinol and beverages. There were no significant correlations between IgG anti-BP180NC16A antibody levels and intake of nutrients/foods. The BPDAI score for cutaneous blisters/erosions significantly positively correlated with intake of carbohydrate and negatively with intake of retinol, vitamin A, animal fat, cholesterol, phosphorus, and vitamin B2. The BPDAI score for cutaneous urticaria/erythema significantly negatively correlated with intake of vitamin A. BP patients with mucosal blisters/erosions had a higher intake of cholesterol, n-6 polyunsaturated fatty acid, and eggs, and lower intake of seasoning/spices, compared to patients without BP. CONCLUSION: The supplementation of vitamin A might have prophylactic and/or therapeutic effects on BP.

DOI： 10.1684/ejd.2023.4527

PubMed

researchmap

記述言語：日本語   出版者・発行元：(一社)日本アレルギー学会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Upadacitinib, an oral Janus kinase 1 inhibitor approved for treating atopic dermatitis (AD), can cause adverse events such as herpes zoster (HZ) and acne. We aimed to identify background factors predicting the occurrence of HZ and acne during upadacitinib treatment in patients with AD. From August 2021 to December 2022, 112 Japanese patients with moderate-to-severe AD (aged ≥12 years) were treated with upadacitinib 15 mg/day (78 patients) or 30 mg/day (34 patients) plus topical corticosteroids or delgocitinib limited to head and neck for 3-9 months. AD patients with the occurrence of HZ during upadacitinib treatment had higher incidences for history of HZ and of bronchial asthma than those without in the upadacitinib 15 mg, 30 mg, and whole groups. AD patients with occurrence of HZ had higher pretreatment values of lactate dehydrogenase and eczema area and severity index on head and neck compared to those without in the upadacitinib 15 mg and whole groups. Logistic regression analysis revealed that history of HZ was associated with the occurrence of HZ in the upadacitinib 15 mg and whole groups. The proportion of underage patients (<18 years) was higher in patients with occurrence of acne compared to those without in the upadacitinib 30 mg group, but no significant differences were found in the other background factors between the two patient populations. History of HZ may predict the occurrence of HZ during upadacitinib treatment in patients with AD.

DOI： 10.1111/1346-8138.16879

PubMed

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

DOI： 10.1111/1346-8138.16866

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

This is the English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors (JAK1 and tyrosine kinase 2 [TYK2] inhibitors) in the treatments of psoriasis. Several cytokines, such as interleukin (IL)-6, IL-7, IL-12, IL-21, IL-22, IL-23, interferon (IFN)-α, and IFN-γ, are involved in the pathogenesis of psoriasis (including psoriatic arthritis). As oral JAK inhibitors hinder the JAK-signal transducers and activators of transcription signal transduction routes involved in the signal transduction of these cytokines, they may be effective for the treatment of psoriasis. JAK has four types: JAK1, JAK2, JAK3, and TYK2. Regarding the use of oral JAK inhibitors for the treatment of psoriasis in Japan, indications of the JAK1 inhibitor upadacitinib were extended also to psoriatic arthritis in 2021, and the use of the TYK2 inhibitor deucravacitinib for plaque-type psoriasis, pustular psoriasis, and erythrodermic psoriasis became covered by health insurance in 2022. This guidance was developed for board-certified dermatologists who specialize in the treatment of psoriasis and to promote the proper use of oral JAK inhibitors. In the package inserts and guides for appropriate use, upadacitinib and deucravacitinib are classified as a "JAK inhibitor" and a "TYK2 inhibitor", respectively, and it is possible that there may be differences in safety between the two drugs. The safety of these drugs will be evaluated for the future by the postmarketing surveillance for molecularly targeted drugs for psoriasis of the Japanese Dermatological Association.

DOI： 10.1111/1346-8138.16797

PubMed

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Itching and skin pain are bothersome symptoms of psoriasis, but evidence is limited regarding the treatment effectiveness on these symptoms in daily clinical settings. We assessed the changes in the levels of itching and skin pain after brodalumab treatment in Japanese patients with psoriasis using patient-reported outcomes (PROs). Patients with psoriasis who have inadequate response to existing treatments were enrolled in the single-arm, open-label, multicenter, prospective ProLOGUE study and received brodalumab 210 mg subcutaneously in daily clinical practice. Psoriasis Area and Severity Index (PASI) and PRO assessments were performed at baseline and weeks 12 and 48. Seventy-three patients (men, 82.2%; median age, 54.0 years) were enrolled. The Itch Numeric Rating Scale (NRS; p < 0.0001 at weeks 12 and 48) and Skin Pain NRS (week 12, p = 0.0004; week 48, p < 0.0001) scores significantly decreased from baseline. The Itch NRS score was significantly higher in patients with a Dermatology Life Quality Index (DLQI) score of ≥2 (vs. 0/1; p < 0.0001 at weeks 12 and 48) and in patients with a Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) global satisfaction domain score of ≤70% (vs. >70%; week 12, p = 0.0120; week 48, p = 0.0348). The Itch NRS score cutoff value for achieving a PASI score of ≤2, DLQI score of 0/1, and TSQM-9 global satisfaction domain score of >70% was 1 at week 12 and 0 at week 48. Brodalumab treatment was associated with improvement in itching and skin pain in Japanese patients with psoriasis. An Itch NRS score of 0 can be a long-term treatment goal for psoriasis (Japan Registry of Clinical Trials identifier: jRCTs031180037).

DOI： 10.1111/1346-8138.16682

PubMed

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

掲載種別：研究論文（学術雑誌）   出版者・発行元：MDPI AG  

Basal cell carcinoma (BCC) is the most common cutaneous malignancy, usually occurring in sun-exposed areas. Although BCC in the scrotal region is uncommon, it carries a higher risk of metastasis than BCC at other sites. Here, we report two cases of BCC that developed in the scrotal region: Case 1 presented as a superficial nodule and Case 2 as a subcutaneous nodule. Histopathologically, both tumors lacked continuity with the surface epidermis and formed an intradermal nodule. In Case 1, BCC occurred for the first time and presumably developed de novo. Case 2 underwent excision of a scrotal BCC 5 years previously, and the histopathological diagnosis at that time was nodular BCC. However, when the original specimen was re-examined, it was determined that, although the tumor had been completely resected, part of the lesion had moved away from the nodular area to represent a micronodular phenotype, an aggressive BCC subtype. We hypothesized that partial evolution from a nodular to a micronodular phenotype may have contributed to the recurrence of BCC in Case 2.

DOI： 10.3390/dermatopathology10020019

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Atopic dermatitis (AD) is a chronic inflammatory skin disease with severe itch. The eosinophil-to-lymphocyte ratio (ELR), neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR) are reported to reflect itch or the severity of AD. We examined if these parameters may act as indicators for therapeutic effects of the Janus kinase 1 inhibitor upadacitinib for patients with AD in real-world clinical practice. Between August 2021 and September 2023, 65 Japanese patients (aged ≥ 12 years) with moderate to severe AD were treated with 15 mg/day of oral upadacitinib, plus twice daily topical corticosteroids. Before treatment, the baseline ELR, NLR, MLR, and PLR levels positively correlated with the eczema area and severity index (EASI), while the baseline NLR and PLR levels positively correlated with the peak pruritus-numerical rating scale (PP-NRS). After upadacitinib treatment, ELR and NLR remarkably decreased at week 4 and the reduced levels were maintained until week 24, in parallel with EASI and PP-NRS, while MLR and PLR transiently reduced at week 4, but returned to baseline levels after week 12. The percent reduction of ELR significantly correlated with the percent reductions of EASI and PP-NRS at weeks 4, 12, and 24 of upadacitinib treatment. ELR may act as an indicator for the improvement of clinical signs and itch by upadacitinib treatment in AD.

DOI： 10.3390/jcm12062201

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

The authors evaluated the efficacy and safety of baricitinib, a Janus kinase 1/2 inhibitor, for atopic dermatitis (AD) in real-world practice. From August 2021 to September 2022, 36 patients aged ≥15 years with moderate to severe AD were treated with oral baricitinib 4 mg/day plus topical corticosteroids. Baricitinib improved clinical indexes; the percent reduction at weeks 4 and 12 was a median of 69.19% and 69.98% for the Eczema Area and Severity Index (EASI), 84.52% and 76.33% for the Atopic Dermatitis Control Tool, and 76.39% and 64.58% for Peak Pruritus Numerical Rating Score, respectively. The achievement rate of EASI 75 was 38.89% and 33.33% at weeks 4 and 12, respectively. The percent reduction of EASI in the head and neck, upper limbs, lower limbs, and trunk was 56.9%, 68.3%, 80.7%, and 62.5% at week 12, respectively, with a significant difference between the head and neck versus the lower limbs. Baricitinib decreased thymus and activation-regulated chemokine, lactate dehydrogenase, and total eosinophil count at week 4. Baseline EASI of the head and neck negatively correlated with percent reduction of EASI at week 4, while baseline EASI of the lower limbs positively correlated with percent reduction of EASI at week 12. Treatment-emergent adverse events included elevation of creatine phosphokinase (11.1%), herpes labialis (5.6%), furuncle (8.3%), and exacerbation of AD (1%), without serious treatment-emergent adverse events. In this real-world study, baricitinib was well tolerated for patients with AD and achieved therapeutic effects comparable to those in clinical trials. High baseline EASI of the lower limbs might predict good treatment response at week 12, while high baseline EASI of the head and neck might predict poor treatment response at week 4 in baricitinib treatment for AD.

DOI： 10.1111/1346-8138.16763

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Psoriasis is associated with cardiometabolic and cardiovascular diseases. Biologic therapy targeting tumor necrosis factor (TNF)-α, interleukin (IL)-23, and IL-17 may improve not only psoriasis but also cardiometabolic diseases. We retrospectively evaluated whether biologic therapy improved various indicators of cardiometabolic disease. Between January 2010 and September 2022, 165 patients with psoriasis were treated with biologics targeting TNF-α, IL-17, or IL-23. The patients' body mass index; serum levels of HbA1c, total cholesterol, high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol, triglyceride (TG), and uric acid (UA); and systolic and diastolic blood pressures were recorded at weeks 0, 12, and 52 of the treatment. Baseline psoriasis area and severity index (week 0) positively correlated with TG and UA levels but negatively correlated with HDL-C levels, which increased at week 12 of IFX treatment compared to those at week 0. UA levels decreased at week 12 after ADA treatment compared with week 0. HDL-C levels decreased 52 weeks after IXE treatment. In patients treated with TNF-α inhibitors, HDL-C levels increased at week 12, and UA levels decreased at week 52, compared to week 0. Thus, the results at two different time points (at weeks 12 and 52) were inconsistent. However, the results still indicated that TNF-α inhibitors may improve hyperuricemia and dyslipidemia.

DOI： 10.3390/jcm12051934

PubMed

researchmap

出版者・発行元：金原出版  

DOI： 10.18888/hi.0000003807

CiNii Research

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

This is the English version of Japanese guidance for use of biologics for psoriasis (the 2022 version). As the first biologics for psoriasis in Japan, infliximab and adalimumab, anti-tumor necrosis factor-α antibodies, became available in the field of dermatology in 2010, followed by ustekinumab, an anti-interleukin (IL)-12/IL-23p40 antibody, which was launched in Japan in 2011. Moreover, after 2015, three IL-17 inhibitors, the IL-17A antibody preparations secukinumab and ixekizumab, and an anti-IL-17 receptor antibody preparation brodalumab were marketed. Furthermore, after 2018, the anti-IL23p19 antibody preparations guselkumab and risankizumab, the TNF inhibitor certolizumab pegol, the IL-23 inhibitor tildrakizumab, and the anti-IL-17A/F antibody bimekizumab were marketed. It is important for physicians to select appropriate biologic therapy for each psoriatic patient after due consideration of disease factors, treatment factors, and patient background factors, sharing such information with patients. The followings can be listed as points to be considered for the selection of biologics: drug effects (e.g., strength of effectiveness, time to onset of effectiveness, effectiveness against arthritis, primary failure, secondary failure), safety (e.g., infections, administration-related reactions, and relationships with other comorbidities), convenience for patients (e.g., hospital visit intervals, self-injection, maintenance therapy at clinics, feasibility of drug discontinuation/re-administration), and payment (medical costs) borne by patients. This guidance has been prepared with the aim of allowing dermatologists experienced in the treatment of psoriasis to use biologics appropriately according to the circumstances of individual patients after consideration of the above-mentioned factors.

DOI： 10.1111/1346-8138.16691

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

We performed a retrospective and observational study of patients with psoriasis. The aim of this study was to define the laboratory indicators reflecting the treatment response to tumor necrosis factor (TNF)-α inhibitors and the predictors for the treatment response. From January 2010 to June 2022, 28, 15 and 12 patients with psoriasis were treated with infliximab (IFX), adalimumab (ADA) and certolizumab pegol (CZP), respectively. The values of C-reactive protein (CRP), platelet to lymphocyte ratio (PLR), neutrophil to lymphocyte ratio and monocyte to lymphocyte ratio decreased in parallel with psoriasis area and severity index (PASI) at weeks 12 and 52 of treatment. The percentage reduction of the CRP was correlated with that of the PASI at week 52 in all patients and subgroups treated with IFX. The percentage reduction of the PLR was correlated with that of the PASI at week 52 in all patients. Linear multivariate regression analyses revealed that the presence of scalp lesions was associated with a high percentage reduction of the PASI at week 52 in the ADA subgroup. The CRP and PLR might act as biomarkers reflecting the treatment response to TNF-α inhibitors in patients with psoriasis. The presence of scalp lesions might be a predictive factor for a high treatment response to ADA in patients with psoriasis.

DOI： 10.3390/jcm12030974

PubMed

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

INTRODUCTION: Upadacitinib, an oral, selective Janus kinase inhibitor, is approved in Japan for the treatment of moderate-to-severe atopic dermatitis (AD), a chronic inflammatory skin disease characterized by eczematous morphology and intense itch. METHODS: Rising Up is an ongoing phase 3, randomized, multicenter study evaluating the long-term safety and efficacy of upadacitinib in Japan. Patients with moderate-to-severe AD were randomized 1:1:1 to topical corticosteroids plus upadacitinib 15 mg (UPA15), upadacitinib 30 mg (UPA30), or placebo at baseline; at week 16, placebo patients were rerandomized 1:1 to UPA15 or UPA30 (plus topical corticosteroids per investigator discretion). This 2-year interim analysis evaluated safety and efficacy through 112 weeks (data cutoff date: 11 August 2021). Adverse events (AEs), AEs of special interest (AESIs), and laboratory data were assessed. Efficacy assessments included ≥ 75% and ≥ 90% improvement from baseline in Eczema Area and Severity Index (EASI 75/90), achievement of clear or almost clear on the validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD 0/1), and ≥ 4-point improvement in the Worst Pruritus Numerical Rating Scale (WP-NRS). RESULTS: A total of 272 patients were enrolled and 242 were ongoing at data cutoff (UPA15, n = 120; UPA30, n = 122). After 112 weeks of treatment, serious AEs, AEs leading to discontinuation, and most AESIs were generally infrequent, and rates were similar between the two upadacitinib groups. One event each of rectal cancer and cerebellar hemorrhage was reported in the UPA15 group; no thrombosis events were observed. The most common AEs included acne, nasopharyngitis, and herpes zoster. EASI 75, EASI 90, vIGA-AD 0/1, and WP-NRS response rates were maintained through week 112. CONCLUSION: UPA15 and UPA30 were well tolerated through 112 weeks of treatment with similar safety profiles to short-term studies and demonstrated durable long-term efficacy for the treatment of moderate-to-severe AD in adults and adolescents. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT03661138.

DOI： 10.1007/s13555-022-00842-7

PubMed

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: We previously evaluated blood screening data, including antinuclear antibodies (ANA), before initiating biologic treatment for patients with psoriasis in a real-world setting. However, we did not analyze change in ANA titers after the start of biologics. No previous study has comprehensively investigated change in ANA titers over time in individual patients or the effectiveness of certolizumab pegol or tildrakizumab. OBJECTIVES: This study evaluated change in ANA titers in individual patients during treatment with biologics, including certolizumab pegol and tildrakizumab. METHODS: 111 patients were included in this study. Change in ANA was regarded as significant when the ANA titer was ×80 or more in patients with a previously undetectable ANA titer or when it increased by fourfold or more in those with a detectable ANA titer before treatment. RESULTS: The ratios of patients with a significant change in ANA titer who were treated with a tumor necrosis factor (TNF) inhibitor, interleukin (IL) -17 inhibitor, or IL-23 inhibitor were 34.9% (15/43), 0.0% (0/32), and 0.0% (0/36), respectively. There were 4 patterns of significant change in ANA titer: (i) an increase (n=8), (ii) a decrease after an increase (n=4), (iii) a decrease after an increase with a drug change (n=2), and (iv) an increase after a decrease after an increase (n=1). No symptom suggesting lupus syndrome was noted. CONCLUSIONS: ANA titers must be carefully monitored throughout treatment with biologics, especially TNF inhibitors, and the possibility of lupus-like syndrome should be excluded.

DOI： 10.1272/jnms.JNMS.2023_90-115

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: We previously analyzed data from blood examination screenings, including serum Krebs von den Lungen (KL) -6 level, before starting biologic treatment for psoriasis in a real-world setting. However, we did not follow change in KL-6 level after the initiation of biologics. Furthermore, there has been no follow-up study of certolizumab pegol, risankizumab, or tildrakizumab. This study evaluated change in serum KL-6 levels in patients during treatment with biologics, including certolizumab pegol, risankizumab, and tildrakizumab. METHODS: We analyzed data from 111 patients. Change in KL-6 level was regarded as significant if it increased to greater than 500 U/mL at least once and if the maximum level after treatment with biologics was at least 1.5 times that of the baseline level. RESULTS: KL-6 level significantly changed during treatment with TNF inhibitors, IL-17 inhibitors, and IL-23 inhibitors in 9 (20.9%), 2 (6.3%), and 2 (5.6%) patients, respectively. Mean age, mean baseline KL-6 level, and frequency of TNF inhibitor use were higher in patients with a significant change in KL-6 level than those in patients without a significant change. Ten patients had minor interstitial changes on chest CT scans but no clinical signs suggesting interstitial pneumonia. CONCLUSIONS: Older patients with psoriasis and high baseline KL-6 levels must be carefully monitored during treatment with biologics, especially TNF inhibitors. Monitoring of KL-6 level and chest CT scans is necessary to exclude the possibility of drug-induced interstitial pneumonia.

DOI： 10.1272/jnms.JNMS.2023_90-207

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

PURPOSE: The status of dupilumab self-injection at home is not well understood. We therefore aimed to identify the barriers to adherence to dupilumab self-injection. PATIENTS AND METHODS: This non-interventional open-label study was conducted between March 2021 and July 2021. Patients with atopic dermatitis, bronchial asthma, and chronic rhinosinusitis with nasal polyps receiving dupilumab, from 15 sites, were requested to complete a self-administered questionnaire regarding the frequency and effectiveness of dosing as well as their use and satisfaction with dupilumab. Barriers to adherence were assessed using the Adherence Starts with Knowledge-12. RESULTS: We included 331 patients who used dupilumab for atopic dermatitis (n = 164), chronic rhinosinusitis with nasal polyps (n = 102), and bronchial asthma (n = 65). The median efficacy of dupilumab scored 9.3 on the visual analog scale. Overall, 85.5% of the patients self-injected dupilumab, and 70.7% perfectly complied with the established injection dates. The pre-filled pen was significantly superior to the conventional syringe in terms of usability, operability, ease of pushing the plunger, and patient satisfaction. However, the pre-filled pen caused more pain during self-injection than did the syringe. Multivariate logistic regression analysis showed that adherence decreased with longer dupilumab treatment duration (p = 0.017) and was not associated with age, sex, underlying disease, or device type. There was a difference in responses related to "inconvenience/forgetfulness" between the good and poor adherence groups. CONCLUSION: The pre-filled dupilumab pen was superior to the syringe in terms of usability, operability, ease of pushing the plunger, and satisfaction. Repetitive instructions are recommended for preventing poor adherence to dupilumab self-injection.

DOI： 10.2147/PPA.S389865

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Tumor necrosis factor (TNF) inhibitors, including adalimumab, are widely used to treat refractory psoriatic arthritis (PsA). Although isoniazid chemoprophylaxis is generally effective in preventing reactivation of latent tuberculosis infection (LTBI), prophylactic measures do not fully protect against development of active tuberculosis. We report a rare case of active tuberculosis despite chemoprophylaxis for LTBI in a patient receiving adalimumab for PsA. A 60-year-old Japanese woman who had received a diagnosis of psoriasis at age 35 years presented with arthralgia of the right hand, which she first noticed 2 months previously. Physical examination showed scattered erythematous papules and plaques with scales on her trunk, extremities, and scalp. Her right metacarpophalangeal and proximal interphalangeal joints were swollen and painful, and her right wrist and elbow were painful. PsA was diagnosed and adalimumab was initiated. Because an interferon-γ release assay (IGRA) showed a borderline result at screening, isoniazid was administered as chemoprophylaxis for LTBI. At 22 months after initiation of adalimumab, IGRA was positive and chest CT disclosed centrilobular nodules in both lungs and swelling of multiple lymph nodes. Culture of sputum at 24 months demonstrated Mycobacterium tuberculosis. Active tuberculosis was diagnosed, and treatment with a combination of isoniazid, rifampicin, ethambutol hydrochloride, and pyrazinamide was started. To ensure timely diagnosis and treatment of active tuberculosis, a tuberculosis expert should be consulted at an early stage, with regular screening and monitoring.

DOI： 10.1272/jnms.JNMS.2023_90-610

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

PURPOSE: To investigate the therapeutic effectiveness and safety of Janus kinase 1 inhibitor upadacitinib in adolescent patients with atopic dermatitis (AD). PATIENTS AND METHODS: This study examined therapeutic effectiveness and safety of upadacitinib for 39 Japanese adolescent patients (aged 12-17 years) diagnosed with moderate-to-severe AD from August 2021 to January 2023. The patients were treated with upadacitinib 15 mg/day plus twice daily topical corticosteroids. Total eczema area and severity index (EASI) or EASI on head and neck, upper limbs, lower limbs, and trunk or for erythema, edema/papulation, excoriation, or lichenification, atopic dermatitis control tool (ADCT), peak pruritus-numerical rating scale (PP-NRS), and laboratory indexes were assessed at weeks 0, 4, and 12 of treatment. Treatment-emergent adverse events were recorded. RESULTS: Total EASI or EASI on 4 anatomical sites or for 4 rash types, ADCT, and PP-NRS were significantly reduced at week 4 and 12 compared to week 0. The achievement rates at weeks 4 or 12 were 64.1% or 62.5% for EASI 75, 93.5% or 73.1% for ADCT <7-point, and 80.6% or 60% for PP-NRS ≥4-point improvement, respectively, indicating their peak at week 4 and slight decrease at week 12. The percent reduction of EASI for excoriation was higher than that for lichenification or edema/papulation at week 4 or week 12, respectively. The percent reductions of EASI for erythema and edema/papulation on head and neck were lower than those on lower limbs at week 12. Total eosinophil counts (TEC) and IgE reduced at week 4 compared to week 0 while TARC, IgE, TEC, and LDH increased at week 12 compared to week 4. CONCLUSION: These results suggest therapeutic effectiveness and tolerability of upadacitinib and support its therapeutic usefulness for adolescent AD patients.

DOI： 10.2147/CCID.S439053

PubMed

researchmap

記述言語：英語  

DOI： 10.1111/cea.14267

PubMed

researchmap

出版者・発行元：金原出版  

DOI： 10.18888/hi.0000003685

CiNii Books

CiNii Research

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Folliculosebaceous cystic hamartoma (FSCH) is a rare cutaneous hamartoma consisting of dilated folliculosebaceous units associated with mesenchymal elements. Ansai et al reported that distinctive features of Miescher-type melanocytic nevi (MMCNs) accompanied 4.6% of FSCH; however, there have been no data about how often FSCH features accompany MMCNs. In this study, we used 7829 cases that had been histopathologically diagnosed as MMCNs of the face, neck, and scalp at the Department of Dermatopathology, Nippon Medical School Musashi Kosugi Hospital and observed whether features of FSCH accompanied them. Of the resected MMCNs, 274 of 7829 (3%) were accompanied by features of FSCH. The nose was the most common resection site, followed by the eyebrow area, ear, and cheek. The coexistence rate for the nevi on the nose and features of FSCH was as high as 10%-20%, and its rate increased with age. We found that FSCH appears mostly in seborrheic areas, such as the nose and cheek, which are rich in normal sebaceous glands. This suggests that nevi, especially on and around the nose, may induce FSCH or similar lesions.

DOI： 10.1097/DAD.0000000000002290

PubMed

researchmap

出版者・発行元：金原出版  

DOI： 10.18888/hi.0000003621

CiNii Research

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Among human cutaneous malignancies, basal cell carcinoma is the most common. Solid advances in unveiling the molecular mechanisms of basal cell carcinoma have emerged in recent years. In Gorlin syndrome, which shows basal cell carcinoma predisposition, identification of the patched 1 gene (PTCH1) mutation was a dramatic breakthrough in understanding the carcinogenesis of basal cell carcinoma. PTCH1 plays a role in the hedgehog pathway, and dysregulations of this pathway are known to be crucial for the carcinogenesis of many types of cancers including sporadic as well as hereditary basal cell carcinoma. In this review, we summarize the clinical features, pathological features and hedgehog pathway as applied in basal cell carcinoma. Other crucial molecules, such as p53 and melanocortin-1 receptor are also discussed. Due to recent advances, therapeutic strategies based on the precise molecular mechanisms of basal cell carcinoma are emerging. Target therapies and biomarkers are also discussed.

DOI： 10.3390/ijms231911968

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

This is an abridged edition of English version of the Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021. Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion. In Japan, from the perspective of evidence-based medicine, the current strategies for the treatment of AD consist of three primary measures: (i) use of topical corticosteroids, tacrolimus ointment, and delgocitinib ointment as the main treatment of the inflammation; (ii) topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of apparent exacerbating factors, psychological counseling, and advice about daily life. In the present revised guidelines, the description about three new drugs, namely, dupilumab, delgocitinib, and baricitinib, has been added. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.

DOI： 10.1016/j.alit.2022.06.009

PubMed

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

This is the English version of the Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021. Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion. In Japan, from the perspective of evidence-based medicine, the current strategies for the treatment of AD consist of three primary measures: (i) use of topical corticosteroids, tacrolimus ointment, and delgocitinib ointment as the main treatment of the inflammation; (ii) topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of apparent exacerbating factors, psychological counseling, and advice about daily life. In the present revised guidelines, descriptions of three new drugs, namely, dupilumab, delgocitinib, and baricitinib, have been added. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.

DOI： 10.1111/1346-8138.16527

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

We evaluated the efficacy and safety of upadacitinib, janus kinase 1 inhibitor for atopic dermatitis (AD) in real-world practice. From September 2021 to March 2022, 31 patients with moderate-to-severe AD, aged ≥12 years were treated with oral upadacitinib 15 mg/day plus topical corticosteroids. Upadacitinib reduced clinical indexes compared to baseline levels: percent reduction at week 4 and 12 (median) was 73.6% and 85.6% in eczema area and severity index (EASI); 81.3% and 81.3% in AD control tool (ADCT); and 70% and 75% in peak pruritus numerical rating score (PP-NRS), respectively. The achievement rate of EASI 75 was 51.6% and 67.7% at week 4 and 12, respectively. Upadacitinib reduced serum lactate dehydrogenase and total eosinophil count (TEC) at week 4 and 12, and thymus and activation-regulated chemokine and immunoglobulin E at week 4, compared to baseline levels. Percent reduction of TEC was correlated with that of EASI at week 4 and 12. Baseline TEC was positively correlated with the percent reduction of EASI at week 4. Percent reduction of EASI in female patients was higher than that in male patients at week 4 and 12. Linear multivariate regression analyses revealed that high percent reduction of EASI at week 4 or 12 was associated with high baseline TEC or female gender, respectively. There were no serious treatment-emergent adverse events. Adverse events include acne (5%), elevation of creatine phosphokinase (9.7%), herpes zoster (1%), and AD (1%). Upadacitinib plus topical corticosteroids for patients with AD in the real-world practice was well tolerated and gave therapeutic effects comparable with those in previous clinical trials. The ADCT and PP-NRS rapidly reduced at week 4 while EASI gradually reduced until week 12. The TEC might act both as a predictive factor of response at week 4 and as a biomarker reflecting therapeutic effects in upadacitinib treatment for AD.

DOI： 10.1111/1346-8138.16549

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Psoriasis poses a substantial economic burden by reducing the work productivity of affected patients. We aimed to evaluate the negative impact of plaque psoriasis on work productivity and effectiveness of brodalumab in improving work productivity impairment in real-life employed patients. This analysis was conducted in employed patients from ProLOGUE, an open-label, multicenter, prospective cohort study (Japan Registry of Clinical Trials identifier: jRCTs031180037). Outcomes included association of Work Productivity and Activity Impairment-Psoriasis (WPAI-PSO) domain scores with scores from various patient-reported outcome measures or Psoriasis Area and Severity Index (PASI) scores at baseline. Change from baseline in WPAI-PSO domain scores following brodalumab treatment was also evaluated. Of the 73 patients enrolled, 51, 48, and 40 patients were considered employed at baseline, Week 12, and Week 48 of brodalumab treatment, respectively. In the model adjusted by age and sex, the work productivity loss score correlated with the Dermatology Life Quality Index (DLQI), itch Numeric Rating Scale (NRS), Patient Health Questionnaire-8 (PHQ-8), and skin pain NRS scores (partial Spearman correlation coefficient [ρ] = 0.608, 0.510, 0.461, and 0.424, respectively); presenteeism score correlated with the DLQI, itch NRS, and skin pain NRS scores (ρ = 0.568, 0.500, and 0.403, respectively); and activity impairment score correlated with the DLQI and PHQ-8 scores (ρ = 0.530 and 0.414, respectively). None of the WPAI-PSO domain scores correlated with the PASI score. All WPAI-PSO domain scores (except absenteeism) significantly reduced from baseline to Weeks 12 (p < 0.0001) and 48 (p < 0.001) with brodalumab treatment. In conclusion, work productivity impairment in psoriasis was associated with various subjective symptoms that can be captured using patient-reported outcome measures. Brodalumab treatment improved work productivity in real-life employed patients with plaque psoriasis.

DOI： 10.1111/1346-8138.16517

PubMed

researchmap

出版者・発行元：金原出版  

DOI： 10.18888/hi.0000003435

CiNii Books

CiNii Research

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Atopic dermatitis (AD), a chronic relapsing inflammatory skin disease with a high disease burden, is one of the most common dermatological conditions in Japan. Herein, we report the disease profiles and current AD treatment during 2-year management of Japanese adults with moderate-to-severe AD. ADDRESS-J was a prospective, longitudinal, observational study that evaluated real-world effectiveness and safety of current AD treatments of adult patients with moderate-to-severe AD (Investigator's Global Assessment score 3 or 4) in Japan. The maximum follow-up period was 2 years. Among 300 patients enrolled, 288 had ≥1 post-baseline evaluation and were analyzed (mean age, 35.5 years; 60.1% male). Almost all patients (99.7%) received topical therapy; the most commonly used therapy was topical corticosteroids of the second-highest potency (86.5%) (e.g., 0.1% mometasone furoate) followed by medium-potency topical corticosteroids (50.3%) (e.g., 0.05% clobetasol butyrate). At month 12 of the study, 10.4% of patients had Investigator's Global Assessment 0/1, similarly at month 24 (10.8%). A total of 132 patients (45.8%) had ≥1 AD flare-up during the observation period, with the majority of first flares occurring within the first year of the study. Various physician- and patient-reported outcomes improved considerably during the first 3 months of the study, with only minor changes after this time. In this cohort, 16.7% of patients had skin infections requiring treatment; 7.3% had adverse events (AE) potentially related to treatment; 1.7% had serious AE; and 1.0% had treatment discontinuations due to AE. Limitations include missing data at later timepoints and the inclusion criteria limiting generalizability. In summary, this analysis of the ADDRESS-J study showed that some patients with moderate or severe AD respond to conventional therapies, while others do not. For those with inadequately controlled moderate-to-severe AD, the newly emerged systemic agents, such as biologics, may provide a potential strategy for long-term disease management.

DOI： 10.1111/1346-8138.16485

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Hailey-Hailey disease (HHD) is an autosomal dominant genodermatosis and the defective gene in HHD is ATP2C1, which encodes secretory pathway Ca2+ /Mn2+ ATPase type 1 (SPCA1). Here we report four Japanese HHD patients showing three kinds of mutations with premature termination codons in the ATP2C1 gene, including two novel ones. Patient 1 was a 39-year-old man with a novel heterozygous mutation, c.664dup in exon 8 (p.N215Kfs*26). Patient 2 was a 33-year-old man (the younger brother of patient 1) with the same mutation as patient 1. Patient 3 was a 55-year-old man with a previously reported heterozygous mutation, c.519dup in exon 7 (p.R174Tfs*4). Patient 4 was a 33-year-old woman with a novel heterozygous mutation, c.2640del in exon 27 (p.L881Ffs*10). The clinical characteristics of our four cases varied in disease severity and the response to treatment. The present cases enrich the database of mutational analysis for HHD.

DOI： 10.1111/1346-8138.16353

PubMed

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：英語  

DOI： 10.1111/1346-8138.16287

PubMed

researchmap

記述言語：日本語   出版者・発行元：(一社)日本皮膚悪性腫瘍学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

出版者・発行元：金原出版  

DOI： 10.18888/hi.0000003190

CiNii Research

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

DOI： 10.1111/1346-8138.16293

researchmap

その他リンク： https://onlinelibrary.wiley.com/doi/full-xml/10.1111/1346-8138.16293

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: Real-life evidence on the quality of treatment with brodalumab in patients with plaque psoriasis based on patient-reported outcomes remains limited. OBJECTIVE: To assess the effectiveness of brodalumab in achieving treatment satisfaction for real-life Japanese patients with psoriasis. METHODS: As part of a single-arm, open-label, multicenter, prospective study (ProLOGUE), Psoriasis Area and Severity Index (PASI) scores, body surface area (BSA), and Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) domain scores were assessed at baseline and Weeks 12 and 48 of brodalumab treatment. Patient Global Assessment (PtGA) scores were captured at Weeks 12 and 48. RESULTS: Seventy-five patients were enrolled, of whom 73 received brodalumab. PASI scores and BSA significantly reduced from baseline at Weeks 12 and 48 (all P < 0.0001). Most (90%) patients felt the treatment was effective on the PtGA scale at Weeks 12 and 48. TSQM-9 domain scores significantly improved at Weeks 12 and 48 (all P < 0.0001). A PASI score of ≤ 2 was suggested as a treatment goal for biologic treatment of psoriasis from a receiver operating characteristic curve analysis, although some of the TSQM-9 domain scores did not improve in patients achieving this goal. No new safety signals were observed. CONCLUSION: Treatment with brodalumab was associated with improved objective symptoms and satisfaction in Japanese patients with psoriasis. A PASI score of ≤ 2 as a goal for biologic treatment of psoriasis may be feasible, although achieving this PASI goal alone may be insufficient to clearly improve long-term patient satisfaction (Japan Registry of Clinical Trials identifier: jRCTs031180037).

DOI： 10.1016/j.jdermsci.2022.02.007

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: Systemic atopic dermatitis treatments that have acceptable safety are needed. OBJECTIVE: To evaluate the safety of the oral Janus kinase inhibitor upadacitinib in combination with topical corticosteroids (TCSs) for the treatment of atopic dermatitis. METHODS: In this phase 3, double-blind study (Rising Up), Japanese patients (12-75 years) with moderate-to-severe atopic dermatitis were randomized in a 1:1:1 ratio to receive 15 mg of upadacitinib + TCS, 30 mg of upadacitinib + TCS, or a placebo + TCS (rerandomized in a 1:1 ratio to receive either 15 or 30 mg of upadacitinib + TCS at week 16). Adverse events and laboratory data were assessed for safety. RESULTS: In 272 treated patients, the serious adverse event rates were similar for 15- and 30-mg upadacitinib + TCS at week 24 (15 mg, 56%; 30 mg, 64%) but greater than those for placebo + TCS (42%). Acne (all mild or moderate; none leading to discontinuation) occurred more frequently with upadacitinib + TCS (15 mg, 13.2%; 30 mg, 19.8%) than with placebo + TCS (5.6%). Furthermore, herpes zoster infection (4.4% vs 0%), anemia (1.1% vs 0%), neutropenia (4.4% vs 1.1%), and creatine phosphokinase elevations (2.2% vs 1.1%) occurred more frequently with 30-mg upadacitinib + TCS than with 15-mg upadacitinib + TCS; none of these events were reported with placebo + TCS. No thromboembolic events, malignancies, gastrointestinal perforations, active tuberculosis, or deaths occurred. LIMITATIONS: The limitations included a small sample size and short observation period as well as nongeneralizability of the results beyond Japanese populations. CONCLUSIONS: The results were generally consistent with those of previous reports; no new safety risks were detected.

DOI： 10.1016/j.jdin.2021.11.001

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Psoriasis is a chronic immune-mediated inflammatory skin disease characterized by hyperproliferation of epidermal keratinocytes. Biologics have been available for the treatment of patients with refractory psoriasis since 2010 in Japan, and as of December 2021, 10 biologics were available. The Biologics Review Committee of the Japanese Dermatological Association for Psoriasis recommends blood examination tests for antinuclear antibodies (ANA), Krebs von den Lugen (KL)-6, hepatitis B surface antigen (HBsAg), hepatitis B surface antibodies (HBsAb), hepatitis B core antibodies (HBcAb), hepatitis C virus (HCV) antibodies, HIV antibodies, human T-cell leukemia virus (HTLV)-1 antibodies, β-D-glucan, and the T-cell spot (T-SPOT) test before initiation of biologics at screening. In this study, we evaluated the use of biologics for 127 psoriasis patients and the blood examination screening data before initiation of biologics in the real-world setting. Tumor necrosis factor inhibitors, interleukin (IL)-17 inhibitors and IL-23 inhibitors were initiated for 54 (42.5%), 36 (28.3%), and 37 (29.1%) patients, respectively. The numbers of patients positive for ANA, HBsAg, HBsAb, HBcAb, HCV antibody, HIV antibody, HTLV-1 antibody, and T-SPOT were 27 (21.3%), 0 (0%), 22 (17.3%), 20 (15.7%), three (2.4%), zero (0%), one (0.8%), and 4 (3.1%), respectively. The numbers of patients whose KL-6 and β-D-glucan levels were higher than the reference values were seven (5.5%) and seven (5.5%), respectively. In the real-world setting, it is sometimes unavoidable to use biologics for those patients with abnormal data although careful monitoring is necessary.

DOI： 10.1111/1346-8138.16333

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

We report the case of an 80 year-old woman who developed bilateral lower extremity purpura and renal impairment with proteinuria a few days after a transient fever (day 0). High levels of both anti-streptolysin-O antibody (ASO) and anti-streptokinase antibody (ASK), as well as low levels of coagulation factor XIII in serum were noted. Skin biopsy was performed and showed a leukocytoclastic vasculitis with deposition of IgA and C3 in the cutaneous small vessels, indicating IgA vasculitis in the skin. After initiation of oral prednisolone, the skin lesions showed significant improvement. However, renal function and proteinuria gradually worsened from day 12. Kidney biopsy was performed on day 29, which demonstrated a necrotizing and crescentic glomerulonephritis with mesangial deposition of IgA and C3. In addition, the deposition of galactose-deficient IgA1 (Gd-IgA1) was positive on glomeruli and cutaneous small vessels, indicating that the purpura and glomerulonephritis both shared the same Gd-IgA1-related pathogenesis. In addition, the association between the acute streptococcal infection and the IgA vasculitis was confirmed by the deposition of nephritis-associated plasmin receptor (NAPlr) in glomeruli. The patient was treated with steroid pulse and intravenous cyclophosphamide, in addition to the oral prednisolone treatment. Renal function and proteinuria gradually improved, but did not completely recover, as is typically seen with courses of IgA vasculitis in the elderly. In this case, the streptococcal infectionrelated IgA vasculitis was confirmed pathologically by the deposition of both NAPlr and Gd-IgA1 in glomeruli, as well as Gd-IgA1 in the cutaneous small vessels.

DOI： 10.1007/s13730-022-00684-4

PubMed

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：英語  

Darier's disease (DD) is a rare autosomal dominant genodermatosis caused by mutations in the ATP2A2 gene, which encodes for the sarcoendoplasmic reticulum calcium ATPase type 2 isoform (SERCA2). In epidermal keratinocytes, the decrease in SERCA2 inhibits the transportation of desmosomal proteins to the plasma membrane, resulting in acantholysis and dyskeratosis. We present the first case of DD with a novel missense mutation in the ATP2A2 gene and successfully treated with calcipotriol/betamethasone dipropionate two-compound ointment. A 34-year-old Japanese woman presented with erythema and scales on the scalp and clusters of keratotic papules on the neck and groin. Similar symptoms were observed in her father, younger sister, and daughter. Histopathological examination revealed corps ronds in the granular layer and grains in the horny layer of the epidermis and acantholytic lacuna just above the basal layer. She was diagnosed with DD. A novel heterozygous missense mutation, c.616A>C (p.Asn206His), was detected in the ATP2A2 gene in both the patient and her daughter. The patient was treated with calcipotriol/betamethasone dipropionate two-compound ointment, which resulted in improvement of the skin eruption. This two-compound topical ointment may be a promising therapeutic strategy in the treatment for DD.

DOI： 10.2147/CCID.S354694

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: Three categories of biologics-tumor necrosis factor (TNF) inhibitors, interleukin (IL) -17 inhibitors, and IL-23 inhibitors-are available for treatment of refractory psoriasis. Recent studies have shown that laboratory biomarkers such as peripheral blood neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), monocyte-lymphocyte ratio (MLR), and serum C-reactive protein (CRP) levels are associated with psoriasis or its severity. This study evaluated associations of transition of NLR, PLR, MLR, and CRP with transition of disease activity in psoriasis patients treated with the three categories of biologics. METHODS: Data from 67 patients were analyzed. Associations of transition of psoriasis area and severity index (PASI) score with the abovementioned laboratory markers were evaluated by using a mixed effects model with PASI as the response variable, laboratory markers as fixed effects collectively, and patients as random effects. RESULTS: In an analysis of all the patients, serum CRP and NLR were associated with PASI score (P=0.006 and P=0.001, respectively). In patients treated with TNF inhibitors, CRP and NLR were associated with PASI score (P=0.043 and P=0.002, respectively). In patients treated with IL-17 inhibitors, NLR was associated with PASI score (P=0.001). CONCLUSIONS: NLR appears to be the most reliable biomarker of the effect of treatment with biologics, especially IL-17 inhibitors.

DOI： 10.1272/jnms.JNMS.2022_89-613

PubMed

researchmap

記述言語：日本語   出版者・発行元：(一社)日本アレルギー学会  

researchmap

その他リンク： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J00009&link_issn=&doc_id=20211209410001&doc_link_id=%2Fcw4aller%2F2021%2F007010%2F001%2F1257-1342%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fcw4aller%2F2021%2F007010%2F001%2F1257-1342%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

その他リンク： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J01174&link_issn=&doc_id=20211223220001&doc_link_id=10.14924%2Fdermatol.131.2691&url=https%3A%2F%2Fdoi.org%2F10.14924%2Fdermatol.131.2691&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_2.gif

記述言語：日本語   出版者・発行元：(一社)日本アレルギー学会  

researchmap

その他リンク： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J00009&link_issn=&doc_id=20211209410001&doc_link_id=%2Fcw4aller%2F2021%2F007010%2F001%2F1257-1342%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fcw4aller%2F2021%2F007010%2F001%2F1257-1342%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

出版者・発行元：金原出版  

DOI： 10.18888/hi.0000002969

CiNii Books

CiNii Research

researchmap

その他リンク： https://search.jamas.or.jp/link/ui/2022045474

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞基底細胞癌は本邦でもっとも多い皮膚悪性腫瘍であり,その治療の原則は手術治療である。被髪頭部は可動性に乏しく,有毛部であるという特性をもつため,整容的な問題が生じないように再建術式を選択する必要がある。症例は79歳,男性。左頭部に生じた腫瘍径約30mm大の基底細胞癌に対して3mmマージンで切除し,約40mm大の欠損部に対してピンホイール皮弁を用いて再建した。術後3ヵ月のフォローでも皮弁の壊死は認めず,整容的にも良好な結果が得られた。脱毛斑を残さない被髪頭部の再建法としてピンホイール皮弁は有用であると考えた。

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2021&ichushi_jid=J01266&link_issn=&doc_id=20211122060041&doc_link_id=10.18888%2Fhi.0000002961&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fhi.0000002961&type=%E5%8C%BB%E6%9B%B8.jp_%E3%82%AA%E3%83%BC%E3%83%AB%E3%82%A2%E3%82%AF%E3%82%BB%E3%82%B9&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

記述言語：英語   掲載種別：研究論文（学術雑誌）  

DOI： 10.1111/1346-8138.16156

PubMed

researchmap

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞81歳,男性。肺腺癌の術後再発のため,上皮成長因子受容体に対するチロシンキナーゼ阻害薬であるアファチニブマレイン酸塩を投与されていた。投与開始3年後より四肢に紅斑を生じ,次第に両下腿に浮腫,多量の滲出液,潰瘍を生じるようになった。浮腫の原因となる心機能低下はなく,アファチニブマレイン酸塩による薬剤性浮腫による下腿潰瘍が考えられた。アファチニブマレイン酸塩を中止し,潰瘍治療および局所圧迫により下腿潰瘍は改善した。アファチニブマレイン酸塩内服中に難治性皮膚潰瘍をきたした場合は休薬を考慮する必要がある。

researchmap

その他リンク： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J01266&link_issn=&doc_id=20211122060025&doc_link_id=10.18888%2Fhi.0000002945&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fhi.0000002945&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞51歳,女性。X年8月,口腔内,両眼球の乾燥が出現した。X+1年3月に唾液腺シンチグラフィで唾液の,シルマー試験で涙液の分泌低下が検出され,抗SS-A抗体および抗SS-B抗体陽性で,当院耳鼻咽喉科にてSjoegren症候群と診断された。X+2年12月,前頭部に脱毛を伴う紅斑が出現し,皮膚生検で真皮網状層のムチン沈着を認め,lupus erythematosus tumidusと診断した。X+3年3月,当科にてヒドロキシクロロキン硫酸塩200mg/日と400mg/日を隔日で内服開始し,同年5月には脱毛が軽減し,7月には紅斑も消退した。自験例はSjoegren症候群にlupus erythematosus tumidusを合併した2例目の報告例である。Lupus erythematosus tumidusの発症とSjoegren症候群あるいは抗SS-A抗体との関連については,今後の症例の蓄積と基礎研究による解明が望まれる。

researchmap

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞32歳,女性。1年前より月経前後や咳嗽時に右鼠径部に疼痛が誘発される皮下腫瘤を自覚した。右鼠径部に有痛性・弾性硬の皮下腫瘤を触知し,MRIでは同部位に多房性の腫瘤を認めた。確定診断のため切除を行ったところ,腫瘤は鼠径管内に存在した。病理組織検査では,線維筋性組織内に島状の内膜様組織が散見され,鼠径管内に生じた子宮内膜症と診断した。異所性子宮内膜症に特徴的な画像所見はなく,月経随伴症状を伴わない場合,鼠径部に腫瘤を生じる他の疾患との鑑別が困難であり,治療の主体となる診療科の決定が困難な場合がある。生殖年齢女性の鼠径部に有痛性腫瘤がある場合は,本疾患を考慮し,詳細な問診を行う必要があると考える。

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2021&ichushi_jid=J01266&link_issn=&doc_id=20211122060049&doc_link_id=10.18888%2Fhi.0000002969&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fhi.0000002969&type=%E5%8C%BB%E6%9B%B8.jp_%E3%82%AA%E3%83%BC%E3%83%AB%E3%82%A2%E3%82%AF%E3%82%BB%E3%82%B9&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞81歳,女性。左大腿部帯状疱疹に対してバラシクロビル塩酸塩内服で嘔気が出現したため,ビダラビン点滴投与による加療を行い,経過中に意識障害,激しい振戦などの神経症状を呈した。髄液所見より,ウイルス性髄膜炎を強く疑ったが,臨床像およびビダラビン代謝産物の血中濃度からはビダラビン脳症の存在が強く考えられた。ウイルス性髄膜炎に対してはアシクロビル投与,ビダラビン脳症に対しては補液などの全身管理を行い,神経症状は徐々に改善したが,見当識障害と下肢麻痺が残存した。帯状疱疹治療中に神経症状が出現した際には,ウイルス性髄膜炎および薬剤性脳症の両方を想起した治療を行うことが重要と考える。

researchmap

その他リンク： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J01266&link_issn=&doc_id=20211025230033&doc_link_id=10.18888%2Fhi.0000002903&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fhi.0000002903&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：日本医科大学医学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞70歳代,男性。初診1ヵ月前より全身に水疱が出現した。臨床像および抗BP180NC16Aドメイン抗体陽性から水疱性類天疱瘡と診断し入院とした。ステロイド内服および大量ガンマグロブリン静注療法の併用で加療し,皮疹は改善傾向となった。全身状態は良好であったが,ステロイド漸減中に右肩関節痛が出現し,CRPの上昇もみられた。全身の画像検査などを施行したが感染巣は特定できず,血液培養採取後に抗菌薬の投与を開始した。その後,血液培養でメチシリン感受性黄色ブドウ球菌が検出され,心臓超音波検査で僧帽弁に疣贅がみられ,感染性心内膜炎と診断した。自己免疫性水疱症加療中の感染性心内膜炎合併はまれだが致死的であるため注意を要する。

researchmap

その他リンク： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J01266&link_issn=&doc_id=20211025230035&doc_link_id=10.18888%2Fhi.0000002905&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fhi.0000002905&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: Dupilumab, a fully human monoclonal antibody that blocks signalling pathways of interleukin (IL)-4 and IL-13, is effective in treating patients with atopic dermatitis (AD). We previously showed that transitions of serum thymus and activation-regulated chemokine (TARC) levels and eosinophil numbers were strongly associated with that of AD activity and that the transitions of serum lactate dehydrogenase (LDH) and immunoglobulin E (IgE) levels were weakly and not associated with that of AD activity, respectively, in patients treated without dupilumab. OBJECTIVES: The purpose of this study was to elucidate whether the association of the transition of laboratory marker levels and transition of disease activity in dupilumab-treated AD patients (present study) was different from that in patients who are not treated with dupilumab (previous study). METHODS: Sixty AD outpatients treated with dupilumab were included in this study. Associations between the transition of the eczema area and severity index (EASI) score and those of above-mentioned laboratory marker levels were evaluated using a mixed effects model of EASI as the response variable, laboratory markers as fixed effects and patients as random effects. RESULTS: The transitions of serum TARC and LDH levels were associated strongly with that of AD activity, but the transitions of serum IgE level and eosinophil numbers were associated with that of AD activity intermediately and weakly, respectively. CONCLUSIONS: Laboratory markers are useful for evaluating the effects of treatments for AD, but the meaning of each laboratory marker depends on the drugs used for treatment.

DOI： 10.1111/ajd.13719

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: We previously reported that pre-irradiation with infrared radiation A (IRA) eliminated ultraviolet B (UVB) -induced cyclobutane pyrimidine dimers (CPDs). Accelerated elimination of CPDs could have resulted from enhanced DNA repair and/or enhanced induction of apoptosis. In this study, we examined whether IRA accelerated the elimination of CPDs by enhancing DNA repair, using Xpa knockout (KO) mice, which were deficient in DNA repair. METHODS: We have already generated mice harboring epidermal melanocytes that produce only eumelanin and dominant pheomelanin, and no melanin. To obtain such mice but with impaired DNA repair ability, we backcrossed these mice with Xpa KO mice. Three hours before UVB irradiation, the mice were irradiated with IRA, and CPDs and apoptotic cells were examined. RESULTS: Pre-irradiation of Xpa KO mice with IRA before UVB irradiation could accelerate the removal of CPDs and enhance apoptotic changes. CONCLUSION: These results indicate that the enhancement of UVB-induced apoptosis and acceleration of removal of CPDs by pre-irradiation with IRA does not depend on DNA damage repair.

DOI： 10.1272/jnms.JNMS.2022_89-213

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Adult-onset Still's disease (AOSD) is a systemic autoinflammatory disorder accompanied by skin eruption. However, typical skin eruptions, such as evanescent, salmon-pink erythema, are not specific to AOSD and dermatologists often face difficulty in diagnosing AOSD. Interleukin-18 (IL-18) is believed to be the initiating factor of the inflammatory cascade in AOSD and overproduction of IL-18 contributes to the development of systemic autoinflammatory reactions. Therefore, we examined serum IL-18 levels in the active and inactive phase of 6 Japanese patients with AOSD who visited our dermatology clinic over the past 10 years and compared with other markers, including IL-6, ferritin and C-reactive protein.

DOI： 10.1272/jnms.JNMS.2022_89-114

PubMed

researchmap

掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

DOI： 10.1111/1346-8138.16023

researchmap

その他リンク： https://onlinelibrary.wiley.com/doi/full-xml/10.1111/1346-8138.16023

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

その他リンク： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J01174&link_issn=&doc_id=20210927470001&doc_link_id=10.14924%2Fdermatol.131.2255&url=https%3A%2F%2Fdoi.org%2F10.14924%2Fdermatol.131.2255&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_2.gif

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Psoriasis is a chronic inflammatory skin disease characterized by accelerated tumor necrosis factor-α/interleukin (IL)-23/IL-17 axis. Patients with psoriasis manifest functional defects in CD4+CD25+ forkhead box protein 3 (Foxp3)+ regulatory T cells (Tregs), which suppress the excess immune response and mediate homeostasis. Defects in Tregs contribute to the pathogenesis of psoriasis and may attribute to enhanced inhibition and/or impaired stimulation of Tregs. IL-23 induces the conversion of Tregs into type 17 helper T (Th17) cells. IL-17A reduces transforming growth factor (TGF)-β1 production, Foxp3 expression, and suppresses Treg activity. Short-chain fatty acids (SCFAs), butyrate, propionate, and acetate are microbiota-derived fermentation products that promote Treg development and function by inducing Foxp3 expression or inducing dendritic cells or intestinal epithelial cells to produce retinoic acids or TGF-β1, respectively. The gut microbiome of patients with psoriasis revealed reduced SCFA-producing bacteria, Bacteroidetes, and Faecallibacterium, which may contribute to the defect in Tregs. Therapeutic agents currently used, viz., anti-IL-23p19 or anti-IL-17A antibodies, retinoids, vitamin D3, dimethyl fumarate, narrow-band ultraviolet B, or those under development for psoriasis, viz., signal transducer and activator of transcription 3 inhibitors, butyrate, histone deacetylase inhibitors, and probiotics/prebiotics restore the defected Tregs. Thus, restoration of Tregs is a promising therapeutic target for psoriasis.

DOI： 10.3390/jcm10173880

PubMed

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本アレルギー学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本美容皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本美容皮膚科学会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

IgA vasculitis (IgAV) is the most frequent form of vasculitis in childhood which classically presents with purpura of the lower extremities, joint pain or swelling and abdominal pain. Though it is a self-limiting disease, and its prognosis is generally good, glomerulonephritis is one of the most important complications. IgAV is classified as a small vessel vasculitis, and though glomerulonephritis develops in IgAV, necrotizing arteritis is rarely seen. Here, we present a case of a 13-year-old girl with IgAV, glomerulonephritis, and necrotizing arteritis in the small renal arteries. There have been only a few reports of adult cases of IgAV with necrotizing arteritis in the kidneys, but there have been no pediatric cases. Some previous reports showed a high mortality rate and implied the possibility of overlap with other vasculitides. In the current report, a rare case of IgAV is described which exhibited necrotizing arteritis rather than overlap with another vasculitis, with a relatively typical clinical course for IgAV and laboratory tests.

DOI： 10.1007/s13730-021-00617-7

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Atopic dermatitis (AD) is a chronic eczematous disease characterized by T helper 2 (Th2) -shifted allergic immunity, skin barrier impairment, and pruritus. Oral intake of certain nutrients might help regulate AD. Serum 25-hydroxyvitamin D levels are often low in patients with AD, and oral vitamin D supplementation improves AD. Vitamin D increases regulatory T (Treg) cells, which promote tolerance to allergens and prevent allergic inflammation by inducing expression of filaggrin and cathelicidin in keratinocytes. Vitamin A strengthens Treg cells by inducing expression of forkhead box P3 and inhibits mediator release from mast cells and eosinophils. Serum levels of γ-linolenic acid and its metabolite, dihomo-γ-linolenic acid, are low in patients with AD, and oral γ-linolenic acid improves AD through anti-inflammatory prostaglandin D1 and E1 derived from dihomo-γ-linolenic acid. Eicosapentaenoic acid and docosahexaenoic acid ameliorate AD by suppressing production of leukotriene B4, increasing ceramides in the stratum corneum, and through their metabolites, resolvin E1 and D1, which resolve inflammation. The probiotics Lactobacillus and Bifidobacteria improve the intestinal permeability barrier and induce Treg cells. Zinc levels in serum, hair, and erythrocytes are diminished in patients with AD. Zinc induces forkhead box P3 expression and increases Treg cells, and zinc-finger protein A20 suppresses nuclear factor-κB-dependent expression of inflammatory cytokines and cell-adhesion molecules. Oral supplementation of the above nutrients might have therapeutic or preventive roles in AD.

DOI： 10.1272/jnms.JNMS.2021_88-317

PubMed

researchmap

記述言語：英語  

DOI： 10.1111/1346-8138.15974

PubMed

researchmap

記述言語：日本語   出版者・発行元：(一社)日本皮膚悪性腫瘍学会  

86歳,女性。2018年9月より顔面と体幹部に播種状に淡い小紅斑が出現し,中毒疹としてプレドニゾロンを内服した。翌年2月より両上眼瞼に紅色皮膚結節が出現。血液検査にて可溶性IL-2レセプター4510U/mLと高値であった。悪性リンパ腫を疑って皮膚生検したところ,真皮から皮下組織にかけて大型から中型の核異型のあるリンパ球様単核球が結節状に集簇しており,免疫組織化学染色では,CD79a,bcl-2,MUM-1が結節状に集簇する細胞に陽性,EBV-encoded small RNA-in situ hybridization,CD30,bcl-6,PAX-5が一部の細胞で陽性であった。病変の一部には,CD138陽性の形質細胞様細胞が集簇していたが,κλ鎖の軽鎖偏位はなく,反応性のものと考えた。当初CD20が一部の細胞でしか陽性とならなかったため,診断に苦慮したが,EBV陽性Diffuse large B-cell lymphoma,非特定型と最終診断した。(著者抄録)

researchmap

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞21歳,女性。顔面パック後に生じた左頬部の皮疹に対して,ヒドロコルチゾン酪酸エステル軟膏を外用したところ浸潤性紅斑を生じた。5年後,尋常性ざ瘡に対して,過酸化ベンゾイルゲルを外用したところ紅斑,丘疹を生じた。外用薬の成分別パッチテストでは,ヒドロコルチゾン酪酸エステル軟膏の主剤が陽性,基剤はすべて陰性であった。一方,過酸化ベンゾイルゲルの製品の希釈系列が陽性,基剤はすべて陰性であった。以上よりヒドロコルチゾン酪酸エステルと過酸化ベンゾイルによるアレルギー性接触皮膚炎と診断した。さらに使用経験のないステロイド外用薬でもパッチテスト陽性であり,ステロイド骨格や側鎖の類似性により交叉感作をきたしたと推測した。また,過酸化ベンゾイルはステロイド外用薬とは別個に感作されたと考えた。

researchmap

その他リンク： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J01266&link_issn=&doc_id=20210617060022&doc_link_id=10.18888%2Fhi.0000002692&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fhi.0000002692&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞45歳,男性。初診時,左後頭部の,生下時よりある黄赤色小結節の癒合した局面上に,長径2.5cm大のドーム状に隆起し,びらんと痂皮を伴う淡紅色腫瘤を認めた。病理組織像では,表皮内に外方向性に突出する腫瘍細胞の胞巣を認め,腫瘍胞巣は腺管あるいは乳頭腫構造を呈し,真皮まで浸潤していた。腫瘍細胞は断頭分泌を伴う円柱上皮細胞と小型立方形細胞から構成され,核異型性を示した。腫瘍の下床には,毛包脂腺組織とアポクリン腺が増殖していた。脂腺母斑上に生じたsyringocystadenocarcinoma papilliferumと診断した。Syringocystadenocarcinoma papilliferumは極めてまれであるため,臨床・病理組織学的所見,治療法は確立しておらず,今後,症例の蓄積による検討が望まれる。

researchmap

その他リンク： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J01266&link_issn=&doc_id=20210422110018&doc_link_id=10.18888%2Fhi.0000002488&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fhi.0000002488&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

記述言語：日本語   出版者・発行元：日本臨床皮膚科医会  

researchmap

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞58歳,女性。初診2ヵ月前より右上腕に7×8mm大の暗赤色結節が出現し,皮膚線維腫や偽リンパ腫などを鑑別に腫瘍を摘出した。病理組織学的所見で,真皮から皮下組織に小型のリンパ球様単核球が結節状に浸潤していた。免疫組織化学染色所見と合わせてprimary cutaneous CD4+ small/medium T-cell lymphoproliferative disorderと診断した。切除後6ヵ月,再発はみられない。Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorderはT細胞リンパ腫のひとつとして考えられていたが,予後が良いことから,2016年にリンパ腫ではなくリンパ増殖性疾患を意味する病名に変更された。Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorderと診断した場合は,不必要な治療は行わず,外科的切除または保存的に経過をみることが望ましい。

researchmap

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J01266&link_issn=&doc_id=20210422110034&doc_link_id=10.18888%2Fhi.0000002504&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fhi.0000002504&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

出版者・発行元：金原出版  

DOI： 10.18888/hi.0000002444

CiNii Books

CiNii Research

researchmap

その他リンク： https://search.jamas.or.jp/link/ui/2021163787

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Palmoplantar pustulosis (PPP) is a chronic dermatitis characterized by sterile intra-epidermal pustules associated with erythema and scales on the palms and soles. Tumor necrosis factor (TNF)-α/interleukin (IL)-23/IL-17 inflammatory pathway may be involved in the pathogenesis of PPP, and the skin lesions manifest the enhanced expression of IL-8 in keratinocytes and increased levels of antimicrobial peptide cathelicidin, leucine leucine-37 in vesicles/pustules. Some PPP patients are associated with arthro-osteitis, called pustulotic arthro-osteitis (PAO). Dietary habits may modulate the pathogenesis of PPP, however, have not been investigated in PPP patients. We evaluated dietary habits in adult Japanese PPP patients, using a validated, brief-type self-administered diet history questionnaire, and compared their results to those of age- and sex-matched healthy controls. The results in PPP patients with PAO were compared to those in the patients without. Japanese PPP patients showed higher body mass indices (BMIs), higher intakes of pulses and sugar/sweeteners, and lower intake of vitamin A, compared to those of healthy controls. The bivariate and multivariable logistic regression analysis showed that PPP was associated with high BMI, high intake of pulses, and low intake of vitamin A. The sodium intake and BMI were positively correlated with palmoplantar pustulosis area and severity index (PPPASI). The linear multivariate regression analysis revealed that sodium intake and BMI were predictors of PPPASI. The age and sodium intake in the patients with PAO were lower than those in the patients without. The bivariate and multivariable logistic regression analysis showed that PAO was negatively associated with age and sodium intake. This is the first study showing the dietary habits in patients with PPP. Further studies should clarify if the dietary intervention to correct the BMI and sodium intake will alter the progress of PPP.

DOI： 10.1111/1346-8138.15719

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: Plaque psoriasis significantly affects patients' health-related quality of life. To aid treatment decisions, not only objective assessment by physicians but also subjective assessment by patients is important. OBJECTIVE: To assess the significance of Dermatology Life Quality Index (DLQI) evaluation at the time of biologics introduction in clinical practice in Japanese patients with plaque psoriasis. METHODS: This was a single-arm, open-label, multicenter study. At baseline, Psoriasis Area and Severity Index (PASI) and DLQI scores were measured and stratified based on DLQI scores ≥6/≤5 and PASI scores ≤10/>10. Other patient-reported outcomes assessed included EQ-5D-5L, itch numerical rating scale (NRS), skin pain NRS, Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-8 (PHQ-8), Sleep Problem Index-II (SPI-II), and Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9). RESULTS: Of the 73 enrolled patients, 23 had PASI scores ≤10. Those with PASI/DLQI scores >10/≥6 had a significantly higher median PASI score than those with PASI/DLQI scores >10/≤5 (p = 0.0125). Regardless of PASI scores (>10/≤10), median itch NRS and GAD-7 scores were significantly higher in patients with DLQI scores ≥6 than in those with DLQI scores ≤5 (itch NRS, p = 0.0361 and p = 0.0086, respectively; GAD-7, p = 0.0167 and p = 0.0273, respectively). Patients with PASI/DLQI scores ≤10/≥6 had significantly higher skin pain NRS (p = 0.0292) and PHQ-8 (p = 0.0255) scores and significantly lower median SPI-II scores (p = 0.0137) and TSQM-9 Effectiveness domain scores (p = 0.0178) than those with PASI/DLQI scores ≤10/≤5. CONCLUSION: DLQI may be useful for assessing patients' concerns that cannot be identified by PASI alone while initiating biologics or switching from other biologics in clinical practice.

DOI： 10.1016/j.jdermsci.2021.01.002

PubMed

researchmap

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞10歳,男児。出生時より右耳の発赤・腫脹を数回繰り返し,近医にて抗菌薬内服で対応していた。初診時,右耳前部に瘻孔がみられ,耳前脚部に淡紅色結節があり,周囲に発赤・腫脹を伴っていた。耳瘻孔を考え,抗菌薬内服を行ってから,手術を行った。耳介軟骨の一部を含めて切除した。病理組織学的には,真皮内に重層扁平上皮で裏打ちされた嚢腫構造がみられ,嚢腫内には角化物が含まれており,耳瘻孔と確定診断した。皮膚科領域において,炎症を伴う耳瘻孔と炎症性粉瘤の鑑別は困難である。耳介周囲に肉芽や膿瘍を認めた際は,感染の治療後に瘻孔や陥凹の有無を確認し,両者を鑑別する。耳瘻孔の診断となれば,手術の検討や合併症の評価が重要となる。

researchmap

その他リンク： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J01266&link_issn=&doc_id=20210323070024&doc_link_id=10.18888%2Fhi.0000002444&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fhi.0000002444&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞7歳,女児。躯幹・四肢にそう痒を伴う紅斑,丘疹,痂皮が出現した。膿痂疹性湿疹を疑い,ステロイド外用や内服で治療するも難治性で,1年後に緊満性水疱が出現した。病理組織学的に好中球浸潤を伴う表皮下水疱を呈し,蛍光抗体直接法で基底膜にIgAの線状沈着を認め,1M食塩水剥離皮膚を用いた蛍光抗体間接法で,基底膜表皮側にIgAが陽性であった。小児型linear IgA bullous dermatosis lamina lucida typeと診断した。ジアミノジフェニルスルホン内服で皮疹は消退した。難治性で,そう痒を伴う蕁麻疹様紅斑を診た際には自己免疫性水疱症を考え,病理組織学的検査,蛍光抗体法などの検査を行う必要がある。

researchmap

その他リンク： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J01266&link_issn=&doc_id=20210126100015&doc_link_id=10.18888%2Fhi.0000002345&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fhi.0000002345&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞65歳,男性。初診時,咽頭・喉頭に多数のびらんがあり,左上腕と上背部に小紅斑が散在していた。背部紅斑の病理組織像は表皮下水疱,水疱内と真皮血管周囲のリンパ球,組織球,好酸球の浸潤を呈した。蛍光抗体直接法では表皮真皮境界部にIgG,C3が沈着し,蛍光抗体間接法は患者血清のIgGがsplit skinの表皮側に反応した。免疫ブロット法では患者血清のIgGがBP180のC末端,NC16a,120kDa LAD-1に反応した。抗BP180型粘膜類天疱瘡と診断した。ステロイド全身投与のみで症状は改善せず,血漿交換,免疫グロブリン大量静注療法で改善したが,ステロイド減量に伴い再燃し,ミゾリビン追加により症状は改善した。

researchmap

その他リンク： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J01266&link_issn=&doc_id=20210126100011&doc_link_id=10.18888%2Fhi.0000002341&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fhi.0000002341&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞65歳,男性。初診時,咽頭・喉頭に多数のびらんがあり,左上腕と上背部に小紅斑が散在していた。背部紅斑の病理組織像は表皮下水疱,水疱内と真皮血管周囲のリンパ球,組織球,好酸球の浸潤を呈した。蛍光抗体直接法では表皮真皮境界部にIgG,C3が沈着し,蛍光抗体間接法は患者血清のIgGがsplit skinの表皮側に反応した。免疫ブロット法では患者血清のIgGがBP180のC末端,NC16a,120kDa LAD-1に反応した。抗BP180型粘膜類天疱瘡と診断した。ステロイド全身投与のみで症状は改善せず,血漿交換,免疫グロブリン大量静注療法で改善したが,ステロイド減量に伴い再燃し,ミゾリビン追加により症状は改善した。

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞65歳,女性。背部,乳房下,臍部,頭皮に紅斑と少数の水疱,上下の歯肉にびらん,硬口蓋に血疱が出現した。組織学的に表皮下水疱を呈し,蛍光抗体直接法で表皮基底膜部にIgG,C3cの線状沈着を認め,1M食塩水剥離皮膚を基質とした蛍光抗体間接法で患者血清IgGが表皮側に反応した。免疫ブロット法ではBP180 NC16aとC末端部の組み換え蛋白に対するIgG抗体が検出された。抗BP180型粘膜類天疱瘡と診断。ミノサイクリン塩酸塩,ニコチン酸アミド内服で皮疹,口腔内病変は軽快した。抗BP180 NC16a抗体と抗C末端抗体陽性のMMP患者では,主として前者が皮疹の発症に,後者が粘膜病変の発症に寄与していると考える。

researchmap

その他リンク： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J01266&link_issn=&doc_id=20210126100012&doc_link_id=10.18888%2Fhi.0000002342&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fhi.0000002342&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Psoriasis is a chronic inflammatory skin disease characterized by accelerated tumor necrosis factor-α (TNF-α) /interleukin (IL) -23/IL-17 axis, epidermal hyperproliferation, and dysregulated differentiation. Psoriasis is occasionally associated with autoimmune liver diseases such as autoimmune hepatitis (AIH) or primary biliary cholangitis (PBC), caused by autoimmunity against hepatocyte- or cholangiocyte-specific autoantigens, respectively. Overlap syndrome is a condition in which patients have features of both AIH and PBC. It has been reported that AIH, PBC, or the overlap syndrome can be triggered by certain drug therapies. A 65-year-old Japanese man developed increased serum levels of aspartate and alanine aminotransferases, and positive anti-nuclear and anti-mitochondrial M2 antibodies, along with neutropenia, at 4 weeks of treatment with an anti-IL-17 receptor A antibody brodalumab for generalized pustular psoriasis. Histological evaluation of the liver revealed interface hepatitis and non-suppurative destructive cholangitis, which is compatible with the overlap syndrome of AIH and PBC. This is the first case of AIH/PBC overlap syndrome during treatment with brodalumab for generalized pustular psoriasis. The relationship between brodalumab and AIH/PBC overlap syndrome should be further elucidated. The risk of autoimmune liver diseases in patients with psoriasis treated with brodalumab should be carefully considered.

DOI： 10.1272/jnms.JNMS.2021_88-517

PubMed

researchmap

掲載種別：研究論文（学術雑誌）   出版者・発行元：Korean Dermatological Association and The Korean Society for Investigative Dermatology  

DOI： 10.5021/ad.2021.33.6.593

researchmap

その他リンク： https://anndermatol.org/DOIx.php?id=10.5021/ad.2021.33.6.593

記述言語：英語   掲載種別：研究論文（学術雑誌）  

PURPOSE: Alopecia areata (AA) is characterized by non-scarring, patchy hair loss caused by autoimmune reactions to anagen hair follicles. The pathogenesis of AA may be affected by the diet. However, the dietary habits of patients with AA have not been precisely examined. Therefore, the aim of this study was to investigate the dietary habits of patients with AA in comparison to those of healthy controls. PATIENTS AND METHODS: We evaluated the dietary habits of 70 adult Japanese patients with AA using a brief-type self-administered diet history questionnaire and compared them to the habits of age- and sex-matched healthy controls. RESULTS: Japanese patients with AA had a higher body mass index (BMI) and higher intakes of vitamin C and fruit than the controls. Logistic regression analysis showed that AA was associated with BMI. Retinol intake was positively correlated with severity of alopecia tool (SALT) score, and linear regression analysis revealed that retinol intake was a predictor of SALT score. Retinol intake among patients with moderate to severe AA (ie, a SALT score >25) was higher than that in patients with mild AA (a SALT score ≤25). The mean age of AA patients with atopic dermatitis (AD) was lower than that of AA patients without AD; however, there were no differences in nutrient or food intake between these two groups. Logistic regression analysis showed that the comorbidity AD was negatively associated with age. CONCLUSION: AA was associated with a high BMI, and high retinol intake was a predictor of SALT score. Further studies should be conducted to clarify whether dietary intervention to reduce BMI or limit retinol intake can alter the development or severity of AA.

DOI： 10.2147/CCID.S335440

PubMed

researchmap

記述言語：英語  

DOI： 10.1016/j.jdermsci.2020.09.005

PubMed

researchmap

記述言語：日本語   出版者・発行元：(一社)日本皮膚悪性腫瘍学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本皮膚悪性腫瘍学会  

researchmap

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞6歳,女児。2歳頃より,頭頸部に紅暈を伴う膿疱がみられ,近医を受診した。真菌・細菌培養陰性で,ステロイド薬外用や抗菌薬内服・外用で治療された。皮疹は出没を繰り返すため,精査目的に当科を紹介受診した。ステロイド薬外用で経過観察していたが,皮疹が拡大し,頸部から胸部,臍周囲の地図状の紅斑局面上に弛緩性膿疱が多発した。初診半年後に膿疱部から生検を施行した。組織学的に角層下に好中球性膿疱がみられ,角層下膿疱症と診断した。ステロイド薬,活性型ビタミンD3外用に反応が乏しく,ジアフェニルスルホン25〜75mg/日およびコルヒチン0.5mg/日を内服して皮疹は軽快した。小児角層下膿疱症では,リスク・ベネフィットを考慮して治療を選択すべきである。

researchmap

記述言語：英語  

DOI： 10.1111/1346-8138.15691

PubMed

researchmap

記述言語：日本語   出版者・発行元：東京慈恵会医科大学成医会  

researchmap

その他リンク： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J00884&link_issn=&doc_id=20210823030046&doc_link_id=%2Fcz8jikei%2F2020%2F013501%2F046%2F0040-0040%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fcz8jikei%2F2020%2F013501%2F046%2F0040-0040%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞症例1:42歳,女性。2007年に四肢の紅斑から皮膚生検し病理組織学的所見より円板状紅斑性狼瘡と診断した。2013年から頭頂部に脱毛斑が生じ,脱毛部の皮膚生検でも同様の診断で,2018年からヒドロキシクロロキン硫酸塩200mg/日と400mg/日を隔日で11ヵ月投与し,脱毛が改善した。症例2:43歳,女性。2000年から頭頂部脱毛があり2017年からフルオシノニドとカルプロニウム塩化物水和物を外用したが脱毛斑が拡大した。2019年に皮膚生検し病理組織学的所見より円板状紅斑性狼瘡と診断した。ヒドロキシクロロキン硫酸塩200mg/日と400mg/日を隔日で4ヵ月投与し,脱毛が改善した。本邦で皮膚エリテマトーデスのヒドロキシクロロキン硫酸塩での脱毛改善例は他に2例報告があるが,いずれの症例も脱毛出現後2年以上経過してヒドロキシクロロキン硫酸塩を導入しても脱毛が改善した。

researchmap

記述言語：日本語   出版者・発行元：日本医科大学医学会  

researchmap

記述言語：英語  

DOI： 10.1111/1346-8138.15622

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: Atopic dermatitis (AD) is a common eczematous skin disorder that profoundly reduces the quality of life due to intractable pruritus. Excellent therapeutic success of the anti-interleukin 4 receptor-α antibody dupilumab in clinical trials and a real-world clinical context indicates the crucial roles of interleukin (IL)-4 and IL-13 in the pathogenesis of AD. Along with the clinical improvement in skin scores and pruritus, dupilumab significantly and progressively reduces and normalizes the upregulated expression of T helper type 2 signatures such as Chemokine (C-C motif) ligand (CCL)17, CCL18, CCL22, and CCL26 in the lesional skin of AD. However, no blood/serum biomarkers are known to predict good or poor outcome in patients with AD treated with dupilumab. METHODS: Patients are at least 18 years of age and have moderate-to-severe AD with Eczema Area and Severity Index (EASI) ≥16, Investigator's Global Assessment ≥3, and body surface area ≥10%. We are going to enroll more than 130 subjects from 18 medical facilities. Clinical objective findings will be evaluated by EASI. Subjective symptoms will be assessed by Patient-Oriented Eczema Measure, Numerical Rating Scale for Pruritus (Pruritus-NRS), Skin Comfort-NRS, and Treatment Satisfaction-NRS. We will measure 18 blood/serum biomarkers including % eosinophils in blood cell count, lactate dehydrogenase, total IgE, soluble interleukin 2 receptor, CCL17, CCL18, CCL22, CCL26, CCL27, IL-13, IL-22, IL-24, IL-25, IL-31, IL-33, thymic stromal lymphopoietin, periostin, and squamous cell carcinoma antigen-2. The clinical evaluation and biomarker sampling will be performed at 0, 2, 4, 8, and 16 weeks of dupilumab treatment. We will also perform proteomic analysis (of roughly 300 proteins) of the patients' sera obtained at 0 and 2 weeks of treatment. The primary endpoint is the association between "baseline levels of 18 biomarkers" and "% change from baseline of EASI at 16 weeks of dupilumab treatment." DISCUSSION: This is the first clinical trial to explore the biomarkers, including potential proteomic markers, most strongly associated with improvement in EASI in patients with moderate-to-severe AD treated with dupilumab for 16 weeks (B-PAD study). A limitation is that we will only enroll Japanese patients.

DOI： 10.1097/MD.0000000000022043

PubMed

researchmap

掲載種別：研究論文（学術雑誌）  

BACKGROUND: Atopic dermatitis (AD) is a common eczematous skin disorder that profoundly reduces the quality of life due to intractable pruritus. Excellent therapeutic success of the anti-interleukin 4 receptor-α antibody dupilumab in clinical trials and a real-world clinical context indicates the crucial roles of interleukin (IL)-4 and IL-13 in the pathogenesis of AD. Along with the clinical improvement in skin scores and pruritus, dupilumab significantly and progressively reduces and normalizes the upregulated expression of T helper type 2 signatures such as Chemokine (C-C motif) ligand (CCL)17, CCL18, CCL22, and CCL26 in the lesional skin of AD. However, no blood/serum biomarkers are known to predict good or poor outcome in patients with AD treated with dupilumab. METHODS: Patients are at least 18 years of age and have moderate-to-severe AD with Eczema Area and Severity Index (EASI) ≥16, Investigator's Global Assessment ≥3, and body surface area ≥10%. We are going to enroll more than 130 subjects from 18 medical facilities. Clinical objective findings will be evaluated by EASI. Subjective symptoms will be assessed by Patient-Oriented Eczema Measure, Numerical Rating Scale for Pruritus (Pruritus-NRS), Skin Comfort-NRS, and Treatment Satisfaction-NRS. We will measure 18 blood/serum biomarkers including % eosinophils in blood cell count, lactate dehydrogenase, total IgE, soluble interleukin 2 receptor, CCL17, CCL18, CCL22, CCL26, CCL27, IL-13, IL-22, IL-24, IL-25, IL-31, IL-33, thymic stromal lymphopoietin, periostin, and squamous cell carcinoma antigen-2. The clinical evaluation and biomarker sampling will be performed at 0, 2, 4, 8, and 16 weeks of dupilumab treatment. We will also perform proteomic analysis (of roughly 300 proteins) of the patients' sera obtained at 0 and 2 weeks of treatment. The primary endpoint is the association between "baseline levels of 18 biomarkers" and "% change from baseline of EASI at 16 weeks of dupilumab treatment." DISCUSSION: This is the first clinical trial to explore the biomarkers, including potential proteomic markers, most strongly associated with improvement in EASI in patients with moderate-to-severe AD treated with dupilumab for 16 weeks (B-PAD study). A limitation is that we will only enroll Japanese patients.

DOI： 10.1097/MD.0000000000022043

Scopus

PubMed

researchmap

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞61歳,女性。生下時から右頭頂部に脱毛斑があり,初診2ヵ月前から脱毛斑内に紅色皮膚腫瘍が出現した。当科初診時には,脱毛斑内に紅色隆起性皮膚腫瘍と黒色隆起性皮膚腫瘍が存在した。初回手術で紅色皮膚腫瘍と黒色皮膚腫瘍を切除し,それぞれ有棘細胞癌と毛芽腫であった。2回目の手術で脱毛斑全体を切除し脂腺母斑の病理結果であった。現在,初回手術から術後6ヵ月で有棘細胞癌の再発はない。脂腺母斑から有棘細胞癌を発症することは珍しく,詳細な報告は自験例を含めて邦文および英語文献で32例である。特に,脂腺母斑に有棘細胞癌と毛芽腫を併発した例は,自験例で2例目である。既報32例の臨床病理学的データをまとめたので報告する。

researchmap

記述言語：日本語   出版者・発行元：(一社)日本美容皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本美容皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本美容皮膚科学会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: Chronic spontaneous urticaria (CSU) is defined as the spontaneously appearing weals and/or angioedema for more than 6 weeks. Dietary habits can modulate the pathogenesis of CSU. However, dietary intakes of nutrients or food in CSU patients, compared with healthy controls, have not been examined in quality and quantity. METHODS: We evaluated dietary habits in adult Japanese patients with chronic spontaneous urticaria using a validated, brief-type self-administered diet history questionnaire and compared the results to those of age- and sex-matched healthy controls. The severity of CSU was evaluated using the Urticaria Control Test. RESULTS: Japanese CSU patients showed higher body mass indices, higher intakes of eggs, vegetables other than green/yellow vegetables/mushrooms/algae, cholesterol, folic acid, dietary fibres, vitamin D, vitamin K, Cu, Fe, Pi, Ca, Mg, Na and salt, and lower intake of alcohol, compared to controls. The logistic regression analysis showed that CSU was associated with high body mass index and high intake of eggs. The intake of beverages was higher in uncontrolled CSU patients (Urticaria Control Test ≦11 points) than in controlled patients. The logistic regression analysis showed that uncontrolled CSU was associated with high intake of beverages. The intake of coffee, caffeine-rich and non-alcohol beverage, in uncontrolled CSU patients was higher than that in controlled patients. CONCLUSIONS: Chronic spontaneous urticaria was associated with high body mass index and high intake of eggs. Uncontrolled CSU was associated with high intake of beverages. Further studies should elucidate the relationships of these results with the development or exacerbation of CSU.

DOI： 10.1111/ajd.13283

PubMed

researchmap

記述言語：日本語   出版者・発行元：(株)協和企画  

＜文献概要＞症例のポイント ・薬剤誘発性と考えられる表在播種型汗孔角化症(disseminated superficial porokeratosis:DSP)の1例を報告した.・薬疹の発症が,なんらかの機序で汗孔角化症(porokeratosis:PK)の発症を促した可能性がある.今後同様の症例の蓄積による検証が待たれる.

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Psoriasis is a chronic inflammatory skin disease characterized by accelerated tumor necrosis factor-α/interleukin-23/interleukin-17 axis, hyperproliferation and abnormal differentiation of epidermal keratinocytes. Psoriasis patients are frequently associated with obesity, diabetes, dyslipidemia, cardiovascular diseases, or inflammatory bowel diseases. Psoriasis patients often show unbalanced dietary habits such as higher intake of fat and lower intake of fish or dietary fibers, compared to controls. Such dietary habits might be related to the incidence and severity of psoriasis. Nutrition influences the development and progress of psoriasis and its comorbidities. Saturated fatty acids, simple sugars, red meat, or alcohol exacerbate psoriasis via the activation of nucleotide-binding domain, leucine-rich repeats containing family, pyrin domain-containing-3 inflammasome, tumor necrosis factor-α/interleukin-23/interleukin-17 pathway, reactive oxygen species, prostanoids/leukotrienes, gut dysbiosis or suppression of regulatory T cells, while n-3 polyunsaturated fatty acids, vitamin D, vitamin B12, short chain fatty acids, selenium, genistein, dietary fibers or probiotics ameliorate psoriasis via the suppression of inflammatory pathways above or induction of regulatory T cells. Psoriasis patients are associated with dysbiosis of gut microbiota and the deficiency of vitamin D or selenium. We herein present the update information regarding the stimulatory or regulatory effects of nutrients or food on psoriasis and the possible alleviation of psoriasis by nutritional strategies.

DOI： 10.3390/ijms21155405

PubMed

researchmap

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞66歳,女性。腰部脊柱管狭窄症にリドカイン(1%キシロカイン),トリアムシノロンアセトニド(ケナコルト-A )を用いて仙骨硬膜外ブロック注射を施行したところ,1〜2分後に呼吸困難感,胸痛を自覚し,その後意識消失した。アナフィラキシーショックと診断され,前医で加療後,原因精査のため紹介受診した。被疑薬剤のトリアムシノロンアセトニド注射液中の成分を用いた皮内テストで,添加物として含まれているカルボキシメチルセルロースが陽性となった。カルボキシメチルセルロースはセルロースを原料とする高分子で,人体に対して不活性とされているため,増粘剤として医薬品やさまざまな食品,日用品に使用されている。本剤によるアナフィラキシーの本邦報告例は7例のみと比較的まれであるが,他の物質によるアレルギーと誤認識されている症例が少なからずあるものと推測する。

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Strategic Outlook toward 2030: Japan's Research for Allergy and Immunology (Strategy 2030) is the national research strategy based on Japan's Basic Law on Measures Against Allergic Diseases, a first of its kind worldwide. This strategy was established by a multi-disciplinary committee consisting of administrators of the Ministry of Health, Labour and Welfare of Japan, young and senior experts from various research societies and associations, and representatives of patient and public groups. Whereas the issues of transition, integration, and international collaboration have yet to be solved in this research realm in Japan, identification of unmet needs, digitization of information and transparent procedures, and strategic planning for complex problems (a process dubbed MIERUKA by the Toyota Way) are crucial to share and tackle the same vision and goals. The committee developed three specific actions focusing on preemptive treatment, interdisciplinarity and internationality, and life stage. The real success of Strategy 2030 is made by the spontaneous contributions of doctors, dentists, veterinarians, and other medical professionals; basic and clinical research scientists, research supporters, and pharmaceutical/medical device companies; manufacturers of food, healthcare, and home appliances; and patients, their families, and the public. The hope is to establish a stable society in which people can live long, healthy lives, as free as possible from allergic and immunological diseases, at each individual life stage. This article is based on a Japanese review first reported in Arerugi, introduces the developmental process and details of Strategy 2030.

DOI： 10.1016/j.alit.2020.04.006

PubMed

researchmap

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞70歳,女性。右上腕,右下腿,両大腿に紅色結節が出現した。紅色結節から抗酸菌を検出し,DNA-DNA Hybridization法でMycobacterium abscessusと同定した。クラリスロマイシン400mg/日内服で下肢の結節は治癒した。右上腕の結節は切除し,再発はない。原因菌は後に,PCR法でMycobacterium abscessusの亜種であるMycobacterium abscessus subsp. massilienseと判明した。Mycobacterium abscessusは亜種間で抗菌薬の感受性が異なるが,亜種の鑑別を迅速に行える検査法は存在しないため,治療は多剤併用で開始することが望ましい。

researchmap

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J01266&link_issn=&doc_id=20200629100015&doc_link_id=10.18888%2Fhi.0000002045&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fhi.0000002045&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

記述言語：日本語   出版者・発行元：金原出版(株)  

66歳女性。左上肢の疼痛と紅色丘疹小水疱を主訴に、帯状疱疹と診断のもとバラシクロビル内服を開始したが、症状の改善が乏しく精査加療目的で入院となった。入院時よりアシクロビルの点滴静注を開始したが、入院4日目に左C5-C6の運動麻痺が出現した。本症例は皮疹のデルマトームと同じ髄節レベルの運動麻痺であったことより、帯状疱疹後の運動麻痺と考えられた。そこで、入院5日目よりステロイドパルス(メチルプレドニゾロン)療法を開始したところ、徐々に外転可動領域の改善が認められた。以後、入院10日目からはプレドニゾロンに変更し、入院14日目には外転可動領域は180°と入院前と同様レベルまで改善し、入院20日目に退院となった。

researchmap

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞41歳,女性。1年前に出現した後頸部皮下腫瘤で当科受診。初診時,後頸部に表面平滑で常色,下床との癒着のない23×15mm大で弾性やや軟の皮下腫瘤を認めた。エコーでは,境界明瞭な嚢胞性腫瘤を認めた。病理組織所見では真皮から皮下脂肪織内に境界明瞭な結節性病変がみられ,免疫染色では,腫瘍細胞の多くがadipophilin陽性,一部CK7,EMA陽性であり,cystic sebaceous tumorと診断した。自験例では内臓悪性腫瘍の合併はなく,Muir-Torre症候群の診断基準を満たさない孤発のまれな例であった。

researchmap

その他リンク： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J01266&link_issn=&doc_id=20200602170031&doc_link_id=10.18888%2Fhi.0000001941&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fhi.0000001941&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion, which is frequently encountered in clinical practice. Skin barrier dysfunction leads to enhanced skin irritability to non-specific stimuli and epicutaneous sensitization. In the lesion site, a further inflammation-related reduction in skin barrier function, enhanced irritability and scratching-related stimuli deteriorate eczema, leading to vicious cycle of inflammation. The current strategies to treat AD in Japan from the perspective of evidence-based medicine consist of three primary measures: (i) the use of topical corticosteroids and tacrolimus ointment as the main treatment for the inflammation; (ii) topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of apparent exacerbating factors, psychological counseling and advice about daily life. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.

DOI： 10.1016/j.alit.2020.02.006

PubMed

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：英語  

DOI： 10.1111/1346-8138.15200

PubMed

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞70歳,男性。初診の十数年前から背部に皮膚結節を自覚,徐々に増大し,中央に潰瘍を伴うようになった。淡紅色,弾性硬,中央に潰瘍を伴う15mm大のドーム状皮膚結節があり,ダーモスコピーでは樹枝状血管と潰瘍化,一部に青黒色斑がみられた。病理組織像では,真皮に毛芽細胞様細胞が結節状あるいは索状に増殖し,腫瘍胞巣の辺縁で核の柵状配列,腫瘍胞巣と間質の間に裂隙の形成があり,基底細胞癌と診断した。自験例は日本人の無色素性基底細胞癌としてはまれな躯幹の発症であり,診断に苦慮した。無色素性基底細胞癌のダーモスコピー像では高頻度に樹枝状血管や潰瘍化がみられ,注意深い観察により色素性所見がみられることもあり,診断に有用である。

researchmap

その他リンク： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J01266&link_issn=&doc_id=20200512100013&doc_link_id=10.18888%2Fhi.0000001883&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fhi.0000001883&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本薬学会  

researchmap

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J01316&link_issn=&doc_id=20200417270001&doc_link_id=10.14894%2Ffaruawpsj.56.4_301&url=https%3A%2F%2Fdoi.org%2F10.14894%2Ffaruawpsj.56.4_301&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

記述言語：日本語   出版者・発行元：日本香粧品学会  

DOI： 10.11469/koshohin.44.6

CiNii Books

CiNii Research

researchmap

その他リンク： https://search.jamas.or.jp/link/ui/2021139348

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Trichodysplasia spinulosa-associated polyomavirus (TSPyV or human polyomavirus 8) was identified from patients with trichodysplasia spinulosa, a rare skin disease affecting the faces of immunocompromised patients. Like other polyomaviruses, the TSPyV genome encodes a large T antigen (LT). However, the expression and functions of TSPyV LT in infected cells remain largely unknown. In the present study, we cloned a full-length TSPyV LT cDNA from cells transfected with the full-length of TSPyV LT DNA. Transfection study using green fluorescence protein-tagged LT expression plasmids showed that TSPyV LT was expressed in the nucleus of transfected cells. Analysis of deletion mutants identified a nuclear localization signal in TSPyV LT. Recombinant TSPyV LT exhibited an ATPase activity. TSPyV LT has a chitinase-like domain; however, no chitinase activity was detected. Immunoprecipitation assays revealed that TSPyV LT bound to retinoblastoma 1, but not to p53 in transfected cells. Expression of TSPyV LT in NIH3T3 cells induced colony formation in soft agar, suggesting its transformation activity. These data indicate that TSPyV LT may be associated with the pathogenesis of trichodysplasia spinulosa, which is a hyperplasia of keratinocytes in inner hair follicles.

DOI： 10.7883/yoken.JJID.2019.391

PubMed

researchmap

掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

DOI： 10.1111/1346-8138.15208

researchmap

その他リンク： https://onlinelibrary.wiley.com/doi/full-xml/10.1111/1346-8138.15208

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(株)南江堂  

＜文献概要＞▼乾癬皮疹部では,最終的にIL-17とIL-22から誘導される表皮角化細胞の過増殖が生じている.▼生物学的製剤による治療では,標的となるサイトカインの作用が抑制された結果,細胞レベルで機能変化が起こって効果が発揮される.

researchmap

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J00974&link_issn=&doc_id=20200310080023&doc_link_id=issn%3D0022-1961%26volume%3D125%26issue%3D3%26spage%3D443&url=http%3A%2F%2Fwww.pieronline.jp%2Fopenurl%3Fissn%3D0022-1961%26volume%3D125%26issue%3D3%26spage%3D443&type=PierOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00005_2.gif

記述言語：日本語   出版者・発行元：日本香粧品学会  

刺激を生じる可能性のある成分を無配合とする低刺激性に配慮した固形石鹸を開発し、アトピー性皮膚炎、脂漏性皮膚炎の症状を顔面に有する患者39例(男性9例、女性30例)を対象に、4週間の使用試験を行った。普段使用の洗顔料に替えて、1日に2回～2日に1回の頻度で試験品による洗顔を行わせた。有害事象の発現は1例にみられ、固形石鹸との因果関係が認められる副作用と判断された。使用開始4日後にかゆみと皮疹が悪化し、その後も使用を継続したがかゆみが悪化したため6日後に使用を中止した。有用性について、医師判定では「非常に有用」が27例、「有用」が10例、「やや有用」が1例、「有用性なし」が0例、「好ましくない」が1例であった。自身の肌状態に対するVAS評価では試験開始時に比較し、調査した3項目すべてで有意に上昇していた。試験品はアトピー性皮膚炎患者、脂漏性皮膚炎患者においても安全に使用できる固形石鹸であると考えられた。

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

We report the case of a 59-year-old Japanese woman who developed linear IgA bullous dermatosis during treatment for ulcerative colitis that manifested as pruritic vesicles with erythema on the trunk and scalp. Histopathological examination revealed subepidermal bulla with neutrophil and eosinophil infiltration in the upper dermis. Direct immunofluorescence revealed linear IgA deposits at the basement membrane zone, and indirect immunofluorescence using split skin revealed IgA reaction to the epidermal side (lamina lucida type). We reviewed 33 reported cases of linear IgA bullous dermatosis associated with ulcerative colitis and found that ulcerative colitis preceded the onset of linear IgA bullous dermatosis in 94% of the patients and that IgA-positive patients in split skin indirect immunofluorescence all showed the lamina lucida type, indicating that target antigens for serum IgA antibodies may reside in the lamina lucida. Regarding the pathogenetic association of ulcerative colitis and linear IgA bullous dermatosis, intestinal inflammation may induce the exposure and presentation of intestinal antigens that are cross-reactive to cutaneous antigens, stimulating autoimmune response to antigens of cutaneous basement membrane zones.

DOI： 10.1111/ajd.13121

PubMed

researchmap

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞81歳,女性。初診の4ヵ月前より四肢・躯幹に浮腫性紅斑,水疱が出現した。皮膚生検の結果,類天疱瘡の診断となった。ステロイド投与を開始したが,投与17日目に胸部CTで右肺塞栓があり,ヘパリン投与を開始した。その後貧血進行,巨大下腿血腫を認めたため,抗凝固療法は中止した。血漿交換療法と免疫グロブリン大量静注療法を行い,皮疹は軽快した。海外のコホート研究によると,類天疱瘡患者はコントロール群と比較し肺塞栓症を3.12倍,肺炎を2.94倍発症しやすい。類天疱瘡患者に肺塞栓症が生じた本邦報告例は,2000〜2018年には3例であり類天疱瘡と肺塞栓症の合併は非常にまれと思われるが,肺塞栓症は致死的になりうるので注意すべきである。

researchmap

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J01266&link_issn=&doc_id=20200214130008&doc_link_id=10.18888%2Fhi.0000001788&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fhi.0000001788&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本アレルギー学会  

「免疫アレルギー疾患研究10ヵ年戦略2030」の策定経緯、特徴、その戦略について解説した。医療提供体制の構築に基づく医療の均てん化等、研究開発以外に推進されている取り組みと本研究戦略との位置付けを明確にし、2030年までに目指す詳細な戦略を厚生労働省が初めて策定した。戦略1として、先制的医療等を目指す免疫アレルギーの本態解明に関する基盤研究、戦略2として、免疫アレルギー研究の効果的な推進と社会の構築に関する横断研究、戦略3として、ライフステージ等免疫アレルギー疾患の特性に注目した重点研究が定められている。

researchmap

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J00009&link_issn=&doc_id=20200210450005&doc_link_id=130007797669&url=http%3A%2F%2Fci.nii.ac.jp%2Fnaid%2F130007797669&type=CiNii&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00003_1.gif

掲載種別：研究論文（学術雑誌）  

DOI： 10.1111/1346-8138.15196

PubMed

researchmap

その他リンク： https://onlinelibrary.wiley.com/doi/full-xml/10.1111/1346-8138.15196

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

A 39-year-old Japanese woman presented with a pruritic infiltrated erythematous plaque on the right cheek. Histopathologic analysis of the erythema showed dermal edema, separation of collagen bundles, and nodular perivascular and periadnexal infiltration of lymphocytes in the whole dermis, without epidermal changes. Alcian blue staining intensity was elevated between the collagen bundles, indicating dermal mucinosis. The nodular infiltrates consisted of CD3+ T cell clusters and CD20+ B cell clusters (ratio, approximately 3:1) and included numerous CD123+ cells, indicative of plasmacytoid dendritic cells. Blood analysis revealed serum antinuclear antibody at a titer of 1:160 (homogeneous, speckled pattern). Lupus erythematosus tumidus with pseudolymphomatous infiltrates was diagnosed. Hydroxychloroquine treatment partially improved symptoms; however, the addition of prednisolone was required for complete resolution. Lupus erythematosus tumidus is sometimes accompanied by pseudolymphomatous infiltrates. Dermal mucinosis and the presence of numerous plasmacytoid dendritic cells are useful in differentiating lupus erythematosus tumidus from pseudolymphoma.

DOI： 10.1272/jnms.JNMS.2020_87-208

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Autoimmune hepatitis (AIH) is a chronic inflammation of the liver caused by hepatocyte-specific autoantigens. Psoriasis is a chronic inflammatory skin disease characterized by a skewed interleukin-17 immune response and dysregulated epidermal hyperproliferation and differentiation. Patients with psoriasis have a higher risk of AIH. Some evidence indicates that AIH is triggered by treatment with certain drugs. Brodalumab is a human monoclonal antibody against interleukin-17 receptor A and is used to treat psoriasis. A 70-year-old Japanese man with psoriasis had elevated serum levels of transaminases and bilirubin, positive antinuclear antibodies, and high serum IgG levels after 11 months of brodalumab treatment. Histological analysis of liver tissue revealed interface hepatitis with lymphoplasmacytic infiltration. AIH was diagnosed and treated with prednisolone, which improved his symptoms. This is the first case of AIH during brodalumab treatment for psoriasis. The relationship between brodalumab and AIH should be further examined, and the risk of AIH in psoriatic patients treated with brodalumab should be carefully considered.

DOI： 10.1272/jnms.JNMS.2020_87-607

PubMed

researchmap

記述言語：英語  

Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion. The current strategies to treat AD in Japan from the perspective of evidence-based medicine consist of three primary measures: (i) the use of topical corticosteroids and tacrolimus ointment as the main treatment for the inflammation; (ii) topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of apparent exacerbating factors, psychological counseling and advice about daily life. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.

DOI： 10.1111/1346-8138.15090

PubMed

researchmap

記述言語：英語  

DOI： 10.1111/1346-8138.15081

PubMed

researchmap

記述言語：日本語   出版者・発行元：(一社)日本皮膚免疫アレルギー学会  

researchmap

researchmap

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞64歳,男性。非活動性B型肝炎ウイルスキャリア。初診時,扁平隆起する紅色小結節が頸部,腰背部,両前腕,両下腿に多発集簇していた。病理組織像は非乾酪性類上皮細胞肉芽腫であった。HBs抗原陽性,HBe抗体陽性。眼底検査で網脈絡膜萎縮を認めた。結節型皮膚サルコイド,眼サルコイドーシスと診断した。初診2ヵ月後,顔面にびまん浸潤型サルコイドと考えられる暗紅色斑が出現した。核酸アナログを併用してプレドニゾロン15mg内服を開始し,皮疹は軽快した。自験例ではB型肝炎ウイルスに対するTh1反応の活性化がサルコイドーシスの肉芽腫形成を誘導した可能性がある。B型肝炎ウイルスキャリアにステロイドを全身投与する場合,ウイルス再活性化防止対策が必要である。

researchmap

その他リンク： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2019&ichushi_jid=J01266&link_issn=&doc_id=20191024130010&doc_link_id=10.18888%2Fhi.0000001620&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fhi.0000001620&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

記述言語：日本語   掲載種別：研究論文（学術雑誌）   出版者・発行元：金原出版(株)  

＜文献概要＞79歳,男性。2017年1月に当科を受診。臨床的にはパンツ型紅斑を呈していた。組織学的に癌性リンパ管症を伴う外陰部乳房外Paget病と診断した。多発骨転移,多発リンパ節転移があったためStage IVと診断した。放射線療法とドセタキセル投与にて紅斑局面はほぼ消失した。統合失調症の既往があり,外来での放射線療法,化学療法の施行が困難だったため,上記治療は基本的に入院で施行した。当初は一般病棟入院としたが,徘徊・不眠症状が強く入院継続困難となり,精神科病棟に転棟し精神科管理の下で,幻聴などの陽性症状なく安定した精神状態を維持できた。統合失調症の合併症のある癌患者では,癌治療のための入院中にせん妄の問題を生じることが多い。しかし細かな精神科回診などを行えば,ほとんどの例で入院継続が可能である。

researchmap

記述言語：英語  

DOI： 10.1111/1346-8138.14880

PubMed

researchmap

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞68歳,男性。仕事中に右拇指を硝酸に曝露したが気づかず放置していた。右拇指の腫脹が強くなり受傷3日後に近医を受診し,その翌日に当院を紹介受診した。X線上骨欠損や腐食はなく,スルファジアジン銀クリーム外用のみで経過をみていたが改善がないため,デブリードマンを施行した。壊死組織を除去しても出血が乏しく,さらに脂肪組織を切除し,出血をある程度確認したところで手術終了とした。術後経過は良好で植皮することなく,外用のみで上皮化した。外用のみでの保存的加療で改善がない場合には,積極的にデブリードマンを行うことが必要である。

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   掲載種別：研究論文（学術雑誌）   出版者・発行元：金原出版(株)  

＜文献概要＞79歳,男性。数年前より左前腕に圧痛のある結節を自覚し,当科を初診した。左前腕に12×8mm大の下床との可動性良好な弾性硬の皮下結節を認めた。造影CTではリング状に造影された。全摘除術を行い,病理組織では,血管周皮細胞様パターンがあり,一部に血管を同心円状に細胞が取り巻く像を認めた。αSMA陽性,S100とCD34は陰性であった。これらより,周皮細胞/血管周囲腫瘍である筋周皮腫,グロムス腫瘍,筋線維腫,血管平滑筋腫のうち,組織学的に筋周皮腫と診断した。自験例では,造影CTでリング状に造影されたことが特徴的であった。リング状に造影される疾患は脳内病変を除くとまれであり,本疾患の特徴であるかもしれない。

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2019&ichushi_jid=J01266&link_issn=&doc_id=20190722170015&doc_link_id=10.18888%2Fhi.0000001485&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fhi.0000001485&type=%E5%8C%BB%E6%9B%B8.jp_%E3%82%AA%E3%83%BC%E3%83%AB%E3%82%A2%E3%82%AF%E3%82%BB%E3%82%B9&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

記述言語：英語   掲載種別：研究論文（学術雑誌）  

DOI： 10.3892/ijo.2019.4790

PubMed

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

DOI： 10.1111/1346-8138.14657

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本皮膚悪性腫瘍学会  

researchmap

記述言語：英語  

Moderate to severe atopic dermatitis (AD) has a high disease burden and a significant effect on quality of life. Observational studies are necessary to determine the patient disease burden and long-term disease control in the Japanese population. ADDRESS-J is a non-interventional, observational registry of adult Japanese patients with moderate to severe AD. Herein, we report baseline data from the ADDRESS-J study describing disease characteristics and current treatment practices. At baseline, 300 adult AD patients with Investigator's Global Assessment (IGA) scores (range, 0-4) of 3 (moderate) or 4 (severe) whose treatments for AD were intensified, were assessed for clinical and patient-reported outcomes and current AD treatments. The registry patients' median age was 34.0 years; 60.7% were male and 71.7% had had AD for more than 20 years. At baseline, 220 study patients had an IGA score of 3 and 80 had an IGA score of 4. The median Eczema Area and Severity Index score was 21.7 (range, 0-72), the median body surface area involvement was 46.25%, and the median pruritus numerical rating scale score was 7.0 (range, 0-10); for each of these measures, higher scores represent greater severity. Most registry patients (86.7%) had recently used topical corticosteroids or topical calcineurin inhibitors as treatment for AD. This registry cohort represents a population of Japanese patients with moderate to severe AD and provides an important resource for characterizing the disease burden and evaluating the safety and effectiveness of various AD treatments.

DOI： 10.1111/1346-8138.14787

PubMed

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：英語  

DOI： 10.1111/1346-8138.14601

PubMed

researchmap

記述言語：英語  

DOI： 10.1016/j.jdcr.2019.01.002

PubMed

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本皮膚悪性腫瘍学会  

Merkel細胞癌(MCC)は高齢者の顔面に好発する悪性度の高い腫瘍で、他の皮膚腫瘍と同一部位に合併発生する例も多く報告されている。今回、Bowen病を伴って発症し、CK20とCK7がともに陰性であった、熱傷瘢痕上に生じたMCCの1例を経験した。自験例のようにBowen病を伴うMCCでの所見を集計すると、CK20の陽性率が低い傾向があり、その診断において、chromogranin A、synaptophysin、CD56など他の免疫染色の検討が重要であると考えられた。また、他種上皮悪性腫瘍合併のMCCやCK20陰性のMCCの場合では、MCPyVの陰性例が多いとの報告があり、その発症原因として日光曝露や免疫抑制、放射線曝露、そして本症例のように熱傷等が関与している可能性がある。(著者抄録)

researchmap

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2019&ichushi_jid=J02197&link_issn=&doc_id=20190305270018&doc_link_id=10.5227%2Fskincancer.33.260&url=https%3A%2F%2Fdoi.org%2F10.5227%2Fskincancer.33.260&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_2.gif

記述言語：英語   掲載種別：研究論文（学術雑誌）  

DOI： 10.1186/s40425-019-0534-z

Web of Science

PubMed

researchmap

記述言語：英語  

DOI： 10.1111/ajd.12868

Web of Science

PubMed

researchmap

記述言語：英語  

DOI： 10.1111/ajd.12868

PubMed

researchmap

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞58歳,男性。数日前から右下腿発赤腫脹,発熱が出現し,初診時CRP,WBC,HbA1c高値,CK,血清ミオグロビン,尿中ミオグロビン異常高値であった。LRINEC score高値であったが,臨床所見,造影CTからは壊死性筋膜炎は否定的で,蜂窩織炎に横紋筋融解症を併発したと診断した。無治療の糖尿病が蜂窩織炎によるsick dayの状態になり,高血糖から低カリウム血症,低マグネシウム血症を引き起こし,横紋筋融解症に至ったと考える。自験例では,臨床所見が重度ではないのに比べ,CK,血清および尿中ミオグロビンが異常高値であったことが,壊死性筋膜炎ではないという診断の助けとなった。また,横紋筋融解症では血清カリウムが上昇するが,低カリウム血症を認めたことから,横紋筋融解症の原因を推定できた。

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

DOI： 10.1111/1346-8138.14881

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

DOI： 10.1111/1346-8138.15032

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

researchmap

掲載種別：研究論文（学術雑誌）  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

DOI： 10.1272/jnms.JNMS.2019_86-3

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

DOI： 10.3892/ijo.2019.4790

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

DOI： 10.1007/s00418-018-01767-z

PubMed

researchmap

記述言語：日本語   出版者・発行元：日本組織細胞化学会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

DOI： 10.1111/1346-8138.14601

researchmap

記述言語：日本語   出版者・発行元：(NPO)日本皮膚外科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：金原出版  

DOI： 10.18888/hi.0000000859

CiNii Research

researchmap

記述言語：英語  

DOI： 10.1111/1346-8138.14190

Web of Science

PubMed

researchmap

記述言語：英語  

DOI： 10.1111/1346-8138.14190

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

© 2018 Japanese Dermatological Association Psoriasis is a chronic, relapsing, inflammatory keratotic skin disease. To elucidate the medication adherence and treatment satisfaction, we performed a questionnaire survey using the eight-item Morisky Medication Adherence Scale (MMAS-8) and nine-item Treatment Satisfaction Questionnaire for Medication (TSQM-9) of 163 psoriatic patients who regularly visited hospitals or clinics. To assess the relationship between the MMAS-8/TSQM-9 outcomes and severity of psoriasis, two different clinical severity indices were used: the Psoriasis Area and the Severity Index (PASI) for disease severity and the Psoriasis Disability Index (PDI) for quality of life (QOL) impairment. The MMAS-8 score for oral medication was significantly higher than that for topical medication. The oral and topical MMAS-8 scores were significantly correlated with the PDI score, but not with the PASI score, indicating that QOL impairment lowered treatment motivation. All of the TSQM-9 domain scores (effectiveness, convenience and global satisfaction) were significantly correlated with both the PASI and PDI scores, suggesting that patients whose skin and QOL conditions were under good control had high satisfaction with treatment. Patients treated with biologics had higher satisfaction than those treated with non-biologics.

DOI： 10.1111/1346-8138.14225

Scopus

PubMed

researchmap

掲載種別：研究論文（学術雑誌）  

DOI： 10.1111/1346-8138.14474

PubMed

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：日本皮膚病理組織学会  

researchmap

記述言語：日本語   出版者・発行元：金原出版(株)  

＜文献概要＞36歳,男性。9ヵ月前から右環指に茶褐色斑を自覚し,当科を受診した。右環指側爪郭に鱗屑の付着する辺縁不整な6×3mm大の茶褐色局面があった。ダーモスコピー上Bowen病を疑い,皮膚生検で色素性Bowen病と診断した。初診から1ヵ月後に腫瘍を全切除し,病変からヒト乳頭腫ウイルス(HPV)73型を検出した。HPV陽性の手の爪部Bowen病は過去に69例の報告があり,平均年齢はBowen病全体と比較し若年であった。検出されたHPV型は16型,73型,56型,33型などが多かった。HPVとの関係性が強く指摘されている子宮頸癌で検出されるHPV型と比較し,必ずしも検出率が相関しないと考えられた。

researchmap

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2018&ichushi_jid=J01266&link_issn=&doc_id=20180416200012&doc_link_id=10.18888%2Fhi.0000000662&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fhi.0000000662&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Elsevier B.V.  

Psoriasis vulgaris (PsV) is an autoimmune disease of skin and joints with heterogeneity in epidemiologic and genetic landscapes of global populations. We conducted an initial genome-wide association study and a replication study of PsV in the Japanese population (606 PsV cases and 2,052 controls). We identified significant associations of the single nucleotide polymorphisms with PsV risk at TNFAIP3-interacting protein 1and the major histocompatibility complex region (P = 3.7 × 10−10 and 6.6 × 10−15, respectively). By updating the HLA imputation reference panel of Japanese (n = 908) to expand HLA gene coverage, we fine-mapped the HLA variants associated with PsV risk. Although we confirmed the PsV risk of HLA-C*06:02 (odds ratio = 6.36, P = 0.0015), its impact was relatively small compared with those in other populations due to rare allele frequency in Japanese (0.4% in controls). Alternatively, HLA-A*02:07, which corresponds to the cysteine residue at HLA-A amino acid position 99 (HLA-A Cys99), demonstrated the most significant association with PsV (odds ratio = 4.61, P = 1.2 × 10–10). In addition to HLA-A*02:07 and HLA-C*06:02, stepwise conditional analysis identified an independent PsV risk of HLA-DQβ1 Asp57 (odds ratio = 2.19, P = 1.9 × 10–6). Our PsV genome-wide association study in Japanese highlighted the genetic architecture of PsV, including the identification of HLA risk variants.

DOI： 10.1016/j.jid.2017.10.001

Scopus

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(株)医学書院  

＜文献概要＞要約 症例1:88歳,女性.下腹部の28mm×25mm,表面乳頭状,褐色調の隆起性結節で,ダーモスコピー上,桃白色網状および紅色胞巣状構造が主体であった.臨床像およびダーモスコピー所見より汗孔腫と診断した.症例2:89歳,女性.左下腿後面の直径20mm,皮膚潰瘍と黒色斑を伴う隆起性結節で,ダーモスコピー上,多彩な血管形成がみられた.ダーモスコピー所見より有棘細胞癌と診断した.切除標本病理組織像で2例とも汗孔癌(porocarcinoma:PC)と診断した.PCは,高齢者の下肢に好発する比較的稀な皮膚付属器悪性腫瘍である.近年,PCを含め低色素性腫瘍の臨床診断にダーモスコピー所見が利用されつつある.腹部と下腿のPCを1例ずつ経験したのでダーモスコピー所見を中心に検討した.ダーモスコピー所見で,桃白色無構造内部にヘアピン血管,線状不整血管など多彩な血管増生があればPCも鑑別に挙げるべきである.

researchmap

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2018&ichushi_jid=J01559&link_issn=&doc_id=20180309060015&doc_link_id=10.11477%2Fmf.1412205341&url=https%3A%2F%2Fdoi.org%2F10.11477%2Fmf.1412205341&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：金原出版  

＜文献概要＞47歳,女性。約2年前より左乳輪に褐色斑が出現した。左乳輪と正常皮膚境界部に10×7mm大,6×3mm大の辺縁不整な褐色斑があった。病理組織学的に,表皮連続性に基底細胞様細胞が増殖し,真皮上層に胞巣を形成,胞巣周囲には裂隙を伴っていた。表在型基底細胞癌と診断した。基底細胞癌の発生部位として乳輪縁は比較的まれであり,その発生機序について考察した。

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：金原出版(株)  

神経線維腫(NF),神経鞘腫(SW),神経周膜腫(PN)のうち,複数の腫瘍成分・構築をとるhybrid末梢神経鞘腫瘍の報告が散見される。PN様構築にSWの腫瘍成分をもつhybrid SW/PN(SW/PN)と,PN様構築にNFの腫瘍成分をもつhybrid NF/PN(NF/PN)を経験した。症例1:68歳,女性。左後頸部の7mm大,弾性やや硬,淡紅色結節。S100蛋白,EMA陽性,hybrid SW/PNと診断した。症例2:47歳,女性。右前腕の10×12mm大,弾性やや硬,淡褐色結節。S100蛋白,EMA,CD34陽性,hybrid NF/PNと診断した。末梢神経鞘腫瘍の詳細な観察が必要と考える。(著者抄録)

researchmap

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2018&ichushi_jid=J01266&link_issn=&doc_id=20180214120035&doc_link_id=10.18888%2Fhi.0000000585&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fhi.0000000585&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

DOI： 10.1111/ajd.12643

PubMed

researchmap

記述言語：英語  

DOI： 10.1111/ajd.12643

PubMed

researchmap

記述言語：日本語   出版者・発行元：金原出版(株)  

61歳,女性。2011年乳癌に対し術前化学療法および手術を受けた。以後再発はなく,経過観察されていた。約1ヵ月前より左手掌,右中指,右膝に5mm大の紅色結節が出現し,2015年2月に当科を受診した。切除したところ病理組織学的にすべて汗孔腫であった。初診の約1年後に前胸部および後頸部に紅色結節が多発し再診した。これらもすべて汗孔腫であった。多発性汗孔腫の報告は国内外で過去に自験例を含めて22例あり,そのうち18例では既往に悪性腫瘍を有していた。18例全例で化学療法,放射線照射,幹細胞移植,骨髄移植のいずれかが行われており,汗孔腫の多発と悪性腫瘍治療歴には何らかの関連性があると推測される。(著者抄録)

researchmap

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2018&ichushi_jid=J01266&link_issn=&doc_id=20180123040031&doc_link_id=10.18888%2Fhi.0000000531&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fhi.0000000531&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

記述言語：日本語   出版者・発行元：金原出版(株)  

症例は30歳代女性で、約5年前から左中指屈側先端に皮内結節を自覚し、徐々に増大した。左中指屈側先端に、常色、弾性硬、下床との可動性不良の6mm大の半球状結節があった。神経線維腫、指趾線維角化腫、粘液嚢腫を考え、局所麻酔下に腫瘍辺縁で全切除した。術後6ヵ月の時点で再発はない。病理組織学的所見の弱拡大像では、真皮内に境界明瞭で被膜を有さない、充実性の結節があった。病変は左右対称性類円形で内部は均一に好酸性に染色された。強拡大像では、核異型性の乏しい短紡錘形の核を有する腫瘍細胞が密に分布した。腫瘍細胞が同心円状の構造を呈する部分や柵状に配列する部分があり、間質には膠原線維の増生があった。抗EMA抗体を用いた免疫組織染色では、一部の腫瘍細胞で陽性であった。神経系腫瘍、なかでも硬化性神経周膜腫(SPN)と診断した。

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

researchmap

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

researchmap

DOI： 10.1272/jnms.2018_85-7

PubMed

researchmap

記述言語：英語  

Verrucous carcinoma (VC) is an uncommon, distinct type of well-differentiated squamous cell carcinoma. Here we present two cases of VC, one arising from the lower leg and the other from genital skin. Case 1, a female patient, aged 95 years, had a brownish verrucous plaque on her right lower leg. Histopathologically, epithelial tumor cells grew pushing the stroma, while the basement membrane was intact. No prominent cellular atypia or hyperchromatin was found. Case 2, a male patient, aged 53 years, had a verrucous plaque at the border between his scrotum and inner aspect of his thigh. A pathological diagnosis of VC was made using an excisional specimen. Making a definitive diagnosis of VC is challenging but crucial. Pathological diagnosis using a small specimen might cause underdiagnosis or overdiagnosis. To avoid this, pertinent pathological diagnosis using an ample specimen is required. We also revisited the definition of VC to precisely understand its nature.

DOI： 10.1272/jnms.2018_85-7

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

We report a case of a blue-black nodule on the left upper eyelid of a 77-year-old woman. Dermoscopic examination of the lesion revealed a purple or purple-red homogenous opaque area like that often observed in apocrine gland cysts and a yellow-whitish homogenous structure with arborizing vessels. After resection of the tumor, a final diagnosis of collision of an apocrine gland cyst and a trichoblastoma was made. We should note the possibility that trichoblastoma may exhibit a yellow-whitish homogenous structure in dermoscopy.

DOI： 10.1272/jnms.JNMS.2018_85-54

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：MEDICAL ASSOC NIPPON MEDICAL SCH  

Giant cell tumors of the tendon sheath (GCT-TS) are one of the most common tumors of the hand, along with ganglions. However, occurrence in the toes is far less common. Here we present a rare case of GCT-TS at the middle phalanx level of the flexor digitorum longus tendon sheath. Magnetic resonance imaging showed low intensity both on T1 and T2 weighted images. To the best of our knowledge, our case is the first report of a GCT-TS arising at the middle phalanx level of the flexor digitorum longus tendon sheath of the fourth toe. Although GCT-TS are rare in the toe, they must be included in the differential diagnoses of soft tissue tumors arising in the toes.

DOI： 10.1272/jnms.84.308

Web of Science

PubMed

researchmap

記述言語：英語  

DOI： 10.1111/1346-8138.13939

PubMed

researchmap

記述言語：日本語   出版者・発行元：(株)協和企画  

＜症例のポイント＞皮膚粘液癌と他臓器由来の転移性粘液癌は、病理組織学的には鑑別が困難であるため、全身の検索により、他臓器原発腺癌の皮膚転移を否定することが必要である。自験例では、画像検査、血液検査から転移を疑うような他臓器の病変はなく、皮膚粘液癌の診断に至った。病理組織学的所見において、自験例では腫瘍細胞巣の外側に断頭分泌像がみられたため、アポクリン腺分化と考えた。(著者抄録)

researchmap

記述言語：英語   出版者・発行元：WILEY  

DOI： 10.1111/1346-8138.13625

Web of Science

researchmap

記述言語：英語   出版者・発行元：WILEY  

DOI： 10.1111/1346-8138.13636

Web of Science

PubMed

researchmap

記述言語：英語  

DOI： 10.1111/1346-8138.13625

PubMed

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

56歳、男性。数年前より頭部に結節が出現。徐々に増大し、2016年12月当科初診。後頭部に15×15mmの中心が隆起し、表面糜爛をともなう紅色の結節があった。2017年1月に全摘出術施行。病理組織像では乳頭状汗管嚢胞腺腫、管状乳頭状腺腫とアポクリン腺嚢腫の3つの腫瘍の所見が存在し、近年新しく提唱されたアポクリン分化をともなう管状乳頭状嚢胞状腺腫に相当する腫瘍と診断した。この腫瘍の概念を中心に考察した。(著者抄録)

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: Allergic contact dermatitis (ACD), which is accelerated by interferon (IFN)-γ and suppressed by interleukin (IL)-10 as regulators, is generally self-limited after removal of the contact allergen. Adipose tissue-derived multipotent mesenchymal stem cells (ASCs) potentially exert immunomodulatory effects. Considering that subcutaneous adipose tissue is located close to the site of ACD and includes mesenchymal stem cells (MSCs), the MSCs in adipose tissue could contribute to the self-limiting course of ACD. OBJECTIVE: The aims of the present study were to elucidate the effects of MSCs in adipose tissue on ACD and to examine any cytokine-mediated mechanisms involved. METHODS: Ear thickness in a C57BL/6 mouse model of ACD using contact hypersensitivity (CHS) elicited by 2,4,6-trinitro-1-chlorobenzene was evaluated as a marker of inflammation level. Five and nine mice were injected with ASCs and phosphate-buffered saline (PBS), respectively. After ASC or PBS injection, real-time reverse transcription-polymerase chain reaction and enzyme-linked immunosorbent assay were performed. RESULTS: Histology showed that CHS was self-limited and ear thickness was suppressed by ASCs in a dose-dependent manner. IFN-γ expression in the elicited skin site and regional lymph nodes was significantly lower in ASC-treated mice than in control mice. IL-10 expression did not differ between treated and control mice. The suppressive effects of ASCs on CHS response did not differ between IL-10 knock-out C57BL/6 mice and wild-type mice. CONCLUSION: The present findings suggest that MSCs in adipose tissue may contribute to the self-limiting course of ACD through decreased expression of IFN-γ, but not through increased expression of IL-10.

DOI： 10.5021/ad.2017.29.4.391

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：WILEY  

Actinic keratosis (AK) is a cutaneous cancer in situ which develops as a result of excessive exposure to ultraviolet (UV). Toll-like receptor (TLR)7 agonist imiquimod is a topical immune response modifier and is effective for the treatment of non-melanoma skin cancers. Recently, the diagnostic role of the dermatoscope has been reported in the course of treatment of AK. In addition, mast cells are now considered to contribute to both the innate and adaptive immune systems in topical imiquimod therapy. We assessed the effect of imiquimod treatment by dermatoscopic and immunohistochemical findings in 14 patients with a total of 21 AK lesions. With the dermatoscope, though the mean erythema score was not significantly different between the cured lesions and the unresponsive lesions, the erythema/red pseudo-network ("strawberry") pattern was decreased significantly in the cured lesions. By immunohistochemistry, the number of Ki-67-positive proliferative cells in the epidermis was decreased and that of CD117-positive mast cells in the dermis was increased in the responding lesions. To the best of our knowledge, this is the first study demonstrating that the number of mast cells in the dermis was increased in AK lesions effectively treated with imiquimod. Our present result suggests that mast cells may contribute an antitumor effect in human skin treated with topical imiquimod.

DOI： 10.1111/1346-8138.13821

Web of Science

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：MEDICAL ASSOC NIPPON MEDICAL SCH  

An external dental fistula is a skin manifestation caused by an underlying dental problem. We report a rare case of external dental fistula associated with a fixed cantilever denture. A 77-year-old Japanese woman presented with an enlarging reddish granulomatous lesion on her right cheek that was diagnosed as an external dental fistula. A fixed cantilever denture had initially been attached to her upper jaw with her seven bona fide teeth. However, six teeth were completely lost and the denture was attached to only one tooth, which showed apical periodontitis. Subsequently, the external dental fistula developed. We should keep in mind that a patient with a fixed cantilever denture can suffer from apical periodontitis and a subsequent external dental fistula due to a failure to maintain appropriate oral hygiene.

DOI： 10.1272/jnms.84.198

Web of Science

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：英語  

Actinic keratosis (AK) is a cutaneous cancer in?situ which develops as a result of excessive exposure to ultraviolet (UV). Toll-like receptor (TLR)7 agonist imiquimod is a topical immune response modifier and is effective for the treatment of non-melanoma skin cancers. Recently, the diagnostic role of the dermatoscope has been reported in the course of treatment of AK. In addition, mast cells are now considered to contribute to both the innate and adaptive immune systems in topical imiquimod therapy. We assessed the effect of imiquimod treatment by dermatoscopic and immunohistochemical findings in 14 patients with a total of 21 AK?lesions. With the dermatoscope, though the mean erythema score was not significantly different between the cured lesions and the unresponsive lesions, the erythema/red pseudo-network (&quot;strawberry&quot;) pattern was decreased significantly in the cured lesions. By immunohistochemistry, the number of Ki-67-positive proliferative cells in the epidermis was decreased and that of CD117-positive mast cells in the dermis was increased?in the responding lesions. To the best of our knowledge, this is the first study demonstrating that the number of mast cells in the

DOI： 10.1111/1346-8138.13821

PubMed

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：WILEY  

Background Ustekinumab, a fully human monoclonal antibody against interleukin-12/23, may potentially be effective for severe atopic dermatitis (AD) treatment. Objectives To evaluate efficacy and safety of ustekinumab 45 mg and 90 mg in patients with severe AD.
Methods In this randomized, placebo-controlled, phase II study, Japanese patients (aged 20-65 years) with severe or very severe AD entered a 12-week double-blind treatment period during which they received (1 : 1 : 1) ustekinumab 45 mg, 90 mg or placebo subcutaneous injections at weeks 0 and 4, with follow-up until week 24. The primary efficacy end point was percentage change from baseline in Eczema Area and Severity Index (EASI) score at week 12. Major secondary efficacy end points included the proportion of patients achieving EASI 50, EASI 75, Investigator's Global Assessment score 0-1, change from baseline Atopic Dermatitis Itch Scale and Dermatology Life Quality Index.
Results A total of 79 patients were randomized [ustekinumab 45 mg (n = 24), 90 mg (n = 28), placebo (n = 27)]. Ustekinumab treatment showed nonsignificant improvement in least square mean change from baseline EASI score at week 12 [45 mg: -38.2%, 95% confidence interval (CI) -21.02-19.51; P &lt; 0.94 and 90 mg: -39.8%, 95% CI -21.84-17.14; P &lt; 0.81] vs. placebo (-37.5%). A non-significant improvement in major secondary efficacy end points was observed in both ustekinumab groups vs. placebo. The most common treatment-emergent adverse events were nasopharyngitis and worsened AD (higher in placebo vs. ustekinumab groups).
Conclusions Ustekinumab 45 mg and 90 mg did not demonstrate meaningful efficacy in Japanese patients with severe AD. The treatment was generally well tolerated.

DOI： 10.1111/bjd.15493

Web of Science

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：英語   出版者・発行元：WILEY  

DOI： 10.1111/1346-8138.13815

Web of Science

PubMed

researchmap

記述言語：英語  

DOI： 10.1111/1346-8138.13815

PubMed

researchmap

記述言語：日本語   出版者・発行元：金原出版  

CiNii Books

researchmap

記述言語：英語  

DOI： 10.1111/1346-8138.13835

PubMed

researchmap

記述言語：英語   出版者・発行元：WILEY  

DOI： 10.1111/1346-8138.13567

Web of Science

PubMed

researchmap

記述言語：英語  

DOI： 10.1111/1346-8138.13567

PubMed

researchmap

記述言語：英語   出版者・発行元：JAPANESE SOCIETY ALLERGOLOGY  

DOI： 10.1016/j.alit.2016.12.006

Web of Science

researchmap

記述言語：英語  

DOI： 10.1016/j.alit.2016.12.006

PubMed

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：金原出版  

CiNii Books

researchmap

記述言語：日本語   出版者・発行元：日本皮膚科学会-大阪地方会・京滋地方会  

researchmap

記述言語：日本語   出版者・発行元：日本皮膚病理組織学会  

researchmap

記述言語：日本語   出版者・発行元：(NPO)日本皮膚外科学会  

researchmap

記述言語：日本語   出版者・発行元：日本皮膚科学会-西部支部  

researchmap

記述言語：日本語   出版者・発行元：(NPO)日本皮膚外科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本皮膚悪性腫瘍学会  

researchmap

記述言語：英語   出版者・発行元：WILEY  

DOI： 10.1111/1346-8138.13643

Web of Science

PubMed

researchmap

記述言語：日本語   出版者・発行元：(一社)日本皮膚悪性腫瘍学会  

J-GLOBAL

researchmap

記述言語：英語  

DOI： 10.1111/1346-8138.13615

PubMed

researchmap

記述言語：英語  

DOI： 10.1111/1346-8138.13643

PubMed

researchmap

掲載種別：研究論文（学術雑誌）  

© 2016 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association. Although infliximab is approved for psoriasis, its efficacy is reduced over time in some patients. The aim of this phase III trial is to evaluate efficacy and safety of infliximab dose escalation in Japanese psoriasis patients with loss of efficacy to standard-dose therapy. Patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis or psoriatic erythroderma who showed loss of efficacy to standard-dose therapy received infliximab dose escalation (10 mg/kg every 8 weeks) from weeks 0 to 32. Loss of efficacy was defined as not maintaining 50% reduction in the Psoriasis Area and Severity Index (PASI 50) after achieving PASI 75. Efficacy and safety were evaluated up to week 40. Fifty-one patients received dose escalation and 43 completed the study. PASI 75 and median improvement rate of PASI score at week 40 were 44% and 70.0%, respectively, showing efficacy in skin symptoms. Efficacies in quality of life, nail psoriasis and joint pain were also obtained. Median serum infliximab level increased from less than 0.1 to 1.1 μg/mL from weeks 0 to 40, showing positive correlation between efficacy and serum infliximab level at week 40. Favorable efficacy was observed in patients with detectable serum infliximab levels (≥0.1 μg/mL) at baseline. Incidences of adverse events, serious adverse events, serious infections and serious infusion reactions were 92%, 10%, 4% and 0%, respectively. No marked difference was observed in both efficacy and safety among psoriasis types. No new safety concerns were observed. Infliximab dose escalation was effective and well-tolerated in psoriasis patients with loss of efficacy to standard-dose therapy, suggesting that dose escalation may be a useful therapeutic option for these patients.

DOI： 10.1111/1346-8138.13698

Scopus

PubMed

researchmap

記述言語：英語   出版者・発行元：WILEY  

DOI： 10.1111/1346-8138.13615

Web of Science

PubMed

researchmap

記述言語：日本語   出版者・発行元：(一社)日本アレルギー学会  

researchmap

記述言語：日本語   出版者・発行元：医学書院  

CiNii Books

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：MEDICAL ASSOC NIPPON MEDICAL SCH  

We present a woman with squamous cell carcinomas on both feet in long-standing eczematous lesions. Histopathological examination of biopsies from the both feet revealed highly atypical cells invading the reticular layer of the dermis in the hyperkeratotic lesion and they were associated with surrounding dermatitis with spongiosis. Although the cause and etiology of eczema in our case is unclear, we speculate that the exceptionally long-lasting dermatitis might have induced double SCCs on bilateral feet with an unusual constitution. To the best of our knowledge, this is a first case of SCC on bilateral feet arising in long-standing eczematous lesions.

Web of Science

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：MEDICAL ASSOC NIPPON MEDICAL SCH  

We report a case of syringocystadenoma papilliferum (SCAP) combined with tubular papillary adenoma (TPA) arising on the chest of a 45-year-old Japanese woman. Histopathological examination revealed the characteristic findings of SCAP in the superficial part of the lesion and those of TPA in the deeper part. We reviewed the English literature about this combination. SCAP and TPA have the same cellular components, but show differences of the general structure. The combination of these two neoplasms is more frequent than expected by most dermatopathologists or pathologists. This combination is frequently seen in patients with nevus sebaceus (NS), but it is also found in patients without NS.

Web of Science

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：JAPANESE SOCIETY ALLERGOLOGY  

DOI： 10.1016/j.alit.2016.09.003

Web of Science

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：WILEY  

Psoriasis, a chronic, immune-mediated skin disease characterized by red, scaly plaques, affects approximately 0.3% of the population in Japan. The aim of this open-label study was to evaluate the long-term efficacy and safety of ixekizumab, a humanized, anti-interleukin-17A monoclonal antibody, in Japanese patients with plaque psoriasis (n = 78, including 11 psoriatic arthritis), erythrodermic psoriasis (n = 8) and generalized pustular psoriasis (n = 5). Ixekizumab was administrated s.c. at baseline (week 0, 160 mg), from weeks 2 to 12 (80 mg every 2 weeks), and from weeks 16 to 52 (80 mg every 4 weeks). At week 52, 92.3% of patients with plaque psoriasis achieved Psoriasis Area and Severity Index (PASI) 75, 80.8% achieved PASI 90, 48.7% achieved PASI 100, and 52.6% had remission of plaques (by static Physician Global Assessment, sPGA [0]). Difficult to treat areas of psoriasis (nail or scalp) also responded to ixekizumab. All patients with psoriatic arthritis who were assessed (5/5) achieved an American College of Rheumatology 20 response. Most patients with erythrodermic psoriasis or generalized pustular psoriasis responded to ixekizumab and the clinical outcome was maintained over 52 weeks (75% and 60% of patients achieved sPGA [0, 1] at week 52, respectively). Mostly mild or moderate treatment-emergent adverse events were reported by 79 of 91 patients; the most common were nasopharyngitis, eczema, seborrheic dermatitis, urticaria and injection site reactions. In conclusion, 52-week ixekizumab treatment was efficacious and well tolerated in Japanese patients with plaque psoriasis. Efficacy was also observed in patients with erythrodermic psoriasis, generalized pustular psoriasis and psoriatic arthritis.

DOI： 10.1111/1346-8138.13622

Web of Science

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：JAPANESE SOCIETY ALLERGOLOGY  

Given the importance of appropriate diagnosis and appropriate assessment of cutaneous symptoms in treatment of atopic dermatitis, the basics of treatment in this guideline are composed of (1) investigation and countermeasures of causes and exacerbating factors, (2) correction of skin dysfunctions (skin care), and (3) pharmacotherapy, as three mainstays. These are based on the disease concept that atopic dermatitis is an inflammatory cutaneous disease with eczema by atopic diathesis, multi-factorial in onset and aggravation, and accompanied by skin dysfunctions. These three points are equally important and should be appropriately combined in accordance with the symptoms of each patient. In treatment, it is important to transmit the etiological, pathological, physiological, or therapeutic information to the patient to build a favorable partnership with the patient or his/her family so that they may fully understand the treatment. This guideline discusses chiefly the basic therapy in relation to the treatment of this disease. The goal of treatment is to enable patients to lead an uninterrupted social life and to control their cutaneous symptoms so that their quality of life (QOL) may meet a satisfactory level. The basics of treatment discussed in this guideline are based on the "Guidelines for the Treatment of Atopic Dermatitis 2008" prepared by the Health and Labour Sciences Research and the "Guidelines for the Management of Atopic Dermatitis 2015 (ADGL2015)" prepared by the Atopic Dermatitis Guidelines Advisory Committee, Japanese Society of Allergology in principle. The guidelines for the treatment of atopic dermatitis are summarized in the "Japanese Guideline for the Diagnosis and Treatment of Allergic Disease 2016" together with those for other allergic diseases. Copyright (C) 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V.

DOI： 10.1016/j.alit.2016.12.003

Web of Science

researchmap

記述言語：英語  

DOI： 10.1111/1346-8138.13614

Web of Science

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

DOI： 10.5021/ad.2017.29.2.239

PubMed

researchmap

記述言語：日本語   出版者・発行元：日本医科大学医学会  

<p>A 72-year-old Japanese woman presented in July 2012 with a 5-year history of depigmented areas on the face. On physical examination, she had multiple well-demarcated depigmented areas on the face and neck. She had also experienced increased thirst for the past 3 years. A blood sample was positive for antinuclear and anti-SS-A antibodies. A biopsied specimen from the lower lip showed dense focal lymphoid infiltration in the minor salivary glands. The patient was diagnosed with vitiligo vulgaris associated with Sjögren syndrome. Internal treatment with L-cysteine, tocopherol nicotinate and topical tacrolimus was of limited efficacy. Subsequent excimer light irradiation together with topical vitamin D₃ administration led to repigmentation around the hair follicles without causing photodermatosis. These treatments appear to be effective for patients with vitiligo vulgaris associated with Sjögren syndrome who have no past history of photosensitivity.</p>

DOI： 10.1272/manms.13.97

CiNii Books

researchmap

その他リンク： http://search.jamas.or.jp/link/ui/2017260023

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：WILEY  

DOI： 10.1111/1346-8138.13580

Web of Science

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：英語  

DOI： 10.1111/1346-8138.13467

PubMed

researchmap

記述言語：日本語   出版者・発行元：金原出版(株)  

36歳女性。左乳頭の腫瘤を自覚、徐々に増大するとともに、出血を伴うようになったため受診した。初診時、左乳頭部に8×8×15mm大の紅色調、弾性やや硬、周囲との境界明瞭な隆起性結節があり、乳頭と一体化していた。局所麻酔下に腫瘍切除術を施行し、病理組織学的に乳頭腺腫と診断された。断端陽性であったため経過観察を要したが、現在に至るまで再発は認められていない。

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：WILEY  

DOI： 10.1111/1346-8138.13472

Web of Science

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

DOI： 10.2340/00015555-2489

PubMed

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：JAPANESE SOCIETY ALLERGOLOGY  

DOI： 10.1016/j.alit.2016.07.006

Web of Science

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：英語   出版者・発行元：WILEY-BLACKWELL  

DOI： 10.1111/ijd.13397